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ABSTRACT 
 
Background: Tuberculosis is an important public health problem worldwide 
due to AIDS epidemic. Emergence of multidrug resistance strains of 
Mycobacterium tuberculosis to the 1st line of antituberculosis drugs is on the 
increase .This poses a serious threat and complicates the management of 
tubercles patients as well as HIV patients. The study aimed to detect the rate of 
M. tuberculosis resistant strains and the prevalence of HIV positive among 
tuberculosis patients, as well as to identify the etiological mycobacterium 
isolates using biochemical and molecular methods.  
Method: A descriptive cross-sectional study was conducted in Khartoum state 
during the period from 2006 to 201. The specimens were collected from the 
tuberculosis management units in Khartoum state. A written consent had been 
taken from participants. Epidemiological and clinical data and 252 sputa, blood 
specimens were collected. Sputa were microscopically examined using Ziehl 
Neelsen staining techniques then cultured according to modified Pettrof’s 
method. The isolates were subjected to biochemical tests, molecular 
identification, drug susceptibility testing using the conventional proportion 
method and the Multiplex Allele Specific analysis. The blood specimens were 
tested for HIV using ELISA and the data were analyzed using SSPS version16. 
Results: Two hundred and forty one mycobacteria were isolated from the 
specimens while 11 (4.4%) showed no growth. The results of Duplex- 
polymerase chain reaction and Multiplex were completely concordant with 
those obtained by conventional culture testing, 235(97.5%) were typical 
Mycobacterium tuberculosis complex, and 6(2.5%) were atypical mycobacteria 
species.  
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Twenty five (10%) tuberculosis patients were positive for HIV analysis. 99.2% 
of the study population aged from 15 to 65 years. 
Drug sensitivity tests using proportion method were done for 241 clinical 
isolates. Out of these isolates 235 were typical mycobacterium complex, forty 
six percent  were resistant to one or more of the drugs tested, Resistance to 
anti-tubercular drugs is as follows, 33(14%) of clinical isolates were resistant 
to rifampcin, 33 (14%) toisoniazid, 79(33.6%) to streptomycin and 46 (19.5%) 
to ethambutol.The majority of isoniazid-resistant isolates (84%) were found to 
be associated with katG 315 gene. Regarding rifampcin, the majority were 
found to be associated with genes of rpoB 531 and rpoB526 (70% and 23.3% 
respectively).  
Based on the phenotypic drug susceptibility testing results, 18(7.7%) of the 235 
typical Mycobacteria were identified as multidrug-resistant.  
 Multiplex allele specific-polymerase chain reaction showed different patterns 
of drug susceptibility. The banding pattern revealed the following mutations; 
21(8.9%) for KatG gene and 4(1.7%) for inhA-15 gene, (10.6%) coding for 
isoniazid resistance. For rifampcin (13%), the following mutation were 
detected; 21(8.9%) for rpoB531, 7(3%) for rpoB526 and 2(0.9%) for rpoB516. 
The sensitivity and specificity of Multiplex allele specific-polymerase chain 
reaction compared with conventional phenotypic drug sensitivity tests were 
87.9% and 99.5% for rifampcin, 73% and 99.5% for isoniazid, 67.4% and 
86.8% for ethambutol respectively. 
Conclusion:  
The majority of isoniazid-resistant isolates were found to be associated with 
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katG 315 gene. Hence, this genetic mutation could be selected for detection of 
most isoniazid-resistant mycobacterial isolates. For rifampcin resistant isolates, 
the majority were found to be associated with genes of rpoB 531 and rpoB526. 
Multidrug-resistant rate was 7.7 %. The increasing incidence of multidrug-
resistant tuberculosis worldwide has also placed emphasis on the need for 
earnest search for new drugs. To increase the sensitivity of Multiplex allele 
specific-polymerase chain reaction for detection of multi-drug resistance in 
Mycobacterium tuberculosis further studies are needed to add more genes or 
codons to be included in reaction.  
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αϭήϴϓνήϣκΤϔϟΔγ΍έΪϟ΍ϩάϫϰϓϦϴϛέΎθϤϟ΍ϰοήϤϟ΍ϦϣΔϴΑΎΘϛΔϘϓ΍ϮϣάΧ΍ϢΗ
ϊϤΟϰϓ˯ΪΒϟ΍ϞΒϗϥέΪϟ΍ϭΐδΘϜϤϟ΍ΔϋΎϨϤϟ΍κϘϧΔϳήϳήδϟ΍ϭΔϴ΋ΎΑϮϟ΍ΕΎϧΎϴΒϟ΍ϭΕΎϨϴόϟ΍
ϥέΪϟ΍ΕΎϴμόϟΔϴΑΎΠϳ΍ϢϐϠΑϭϡΩΔϨϴϋϢΗκΤϓΔϨϴϋΎϴΑϮϜγϭήϜϴϣϢϐϠΑ
ΕϻϭΰόϤϟ΍ΖόπΧϭΓέϮτϤϟ΍ϑϭήΘΑΔϘϳήτΑΖϋέίϭϥϮδϠϴϧϞϳίΔϐΒλΔτγ΍ϮΑ
ϯήΟ΍ΪϗϭΕ΍ήτϔΘϤϟ΍ωϮϧΔϓήόϤϟΔϴΌϳΰΠϟ΍ΔϴϨϘΘϟ΍Ε΍έΎΒΘΧ΍ϭΔϳϮϴΣϮϤϴϜϟ΍Ε΍έΎΒΘΧϼϟ
ΘϤϟ΍ϯήϤϠΒϟ΍ΔϠδϠδϟ΍ϞϋΎϔΗΕ΍έΎΒΘΧ΍ϭΔϳΪϴϠϘΘϟ΍ϕήτϟ΍ϝΎϤόΘγΎΑΔϴγΎδΤϟ΍έΎΒΘΧ΍ΩΪό
ΝϼόϟΔϣΪΨΘδϤϟ΍Ε΍έΎϘόϟ΍ΔϣϭΎϘϤΑΔϠμϟ΍Ε΍ΫΕΎϨϴΠϟ΍ω΍Ϯϧ΍ΔϓήόϤϟΕϻϭΰόϤϠϟ
ϰϋΎϨϤϟ΍ιΎμϣΩϻ΍έΎΒΘΧ΍Δτγ΍ϮΑϡΪϟ΍ΕΎϨϴϋκΤϓΎπϳ΍ϢΗΎϤϛϥέΪϟ΍ϰοήϣ
ΓήϴϤΨϟΎΑςΒΗήϤϟ΍ΪϘϟϡ΍ΪΨΘγ΍ϢΗSSPS ΕΎϧΎϴΒϟ΍ϞϴϠΤΗϰϓ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ϥέΪϟ΍νήϤϟΓήΒΘΨϤϟ΍ϝϭϻ΍ϰΗϻΎϛΔϳϭΩϼϟΔϴϧέΪϟ΍ΔϳήϴΘϜΒϟ΍ΕϻϭΰόϤϟ΍ΔϣϭΎϘϣΖϧΎϛ
ϦϴδΒϣΎϔϳήϠϟˬ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Ϊϳ΍ΰϳΎϴϧϭΰϳϻ΍ϰΑςΒΗήΗkatG geneΔϴΒϠϏϻΎϓϦϴδΒϣΎϔϳήϟΎΑκΘΨϳΎϤϴϓΎϣ΍
ΕΎϨϴΠϟΎΑςΒΗήΗrpoB531and rpoB526(70% and 23% ),
ϥ΍ΪΠϧϥέΪϟ΍ΔϳϭΩϻΔϴγΎδΤϟ΍Ε΍έΎΒΘΧ΍Ξ΋ΎΘϧϰϠϋ˯ΎϨΑϦϣ
ϥέΪϟ΍ΔϳϭΩϻΔϣϭΎϘϤϟ΍ΓΩΪόΘϣΎϬϧΎΑΖϓήϋΔϴϧέΪϟ΍Ε΍ήτϔΘϤϟ΍ΕϻϭΰόϣϞϴϠΤΘϟ΍Ξ΋ΎΘϧ
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ϥ΍Ζϓήϋϝ 
katGˬϝ mabA-inhA-15ΔτΒΗήϤϟ΍ΕΎϨϴΠϟ΍ϰϓΕ΍ήϔτϟ΍Ϧϣ
Please purchase PDFcamp Printer on http://www.verypdf.com/ to remove this watermark.
 X
ΎΑΪϳ΍ίΎϴϧϭΰϳϻ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ϦϴδΒϣΎϔϳήϟ΍ 
ωίϮΘΗ ϰΗϻΎϛ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Abbreviations 
 
AFB Acid Fast Bacilli 
AIDS Acquired immune deficiency syndrome 
BCG Bacillus Calmette-Guérin 
BSC Biological Safety Cabinet 
CD4 Cluster of differentiation 4 
CD8 Cluster of differentiation 8 
CDC Centers for Disease Control and Prevention 
DNA Deoxyribonucleotide 
DOTS Directly Observed Therapy Short Course 
DST Drug Susceptibility Testing 
ElISA Enzyme-linked immuno-sorbent assay 
EMB Ethambutol 
HCL Hydrochloric acid 
HIV Human immunodeficiency virus 
HIV/ AIDS 
Human immunodeficiency virus/ acquired immune deficiency 
syndrome 
IDPs Internally displaced persons 
IFN-?  Interferon gama 
IL-2 Interleukin-2  
INH Isoniazid 
Inh-A inhAenoyl acyl reductase gene 
IUATLD International Union Against Tuberculosis and Lung Disease 
Please purchase PDFcamp Printer on http://www.verypdf.com/ to remove this watermark.
 XII
KatG KatG catalase-peroxidase gene 
LTBI Latent TB infection 
L J Lowenstein-Jansen 
MAS-PCR Multipelix Allele Specific 
m-PCR multiplex PCR 
Mm Milimolar 
MDR TB multi-drug-resistant tuberculosis 
MIRU-VNTR 
Mycobacterial Interspersed repetitive Unit-Variable number     
Tandem repeat 
MgCl2 Magnisum chloride 
M.TB Mycobacterium tuberculosis 
MTC Mycobacterium tuberculosis complex 
MOTT Mycobacteria other than tuberculosis 
M. tuberculosis 
Mycobacterium tuberculosis 
 
1N One normality 
NAA Nucleic acid amplification 
NaNO3 Sodium nitrate 
NaOH Sodium Hydroxide 
NTM non-tuberculosis mycobacteria 
NTP National Tuberculosis program 
PZA Pyrazinamide 
Please purchase PDFcamp Printer on http://www.verypdf.com/ to remove this watermark.
 XIII
PCR Polymerase Chain Reaction 
PPD Purified protein derivate 
PPEM potentially pathogenic environmental mycobacteria 
rBCG30 recombinant tuberculosis vaccine 
RFLP Restriction Fragment Length Polymorphism 
RIF Rifampcin 
Rpoß  ß  subunit of RNA polymerase  
RRDR Rifampacin resistant determining region  
SM Streptomycin 
SNP Single Nucleotide Polymorphism 
TB Tuberculosis 
TBMUs Tuberculosis Medical units 
WHO World Health Organization 
XDR-TB Extensively Drug Resistant Tuberculosis 
ZN Ziehl-Neelsen 
 
            
              
             
           
                         
                 
            
Please purchase PDFcamp Printer on http://www.verypdf.com/ to remove this watermark.
 XIV
Table of Content 
 Preface i 
 Dedication  ii 
 Acknowledgements iii 
 Abstract v 
 Arabic abstract viii 
 Abbreviations xi 
 Table of contents xiv 
 List of figures xxii 
 List of tables xxiii 
CHAPTER ONE: INTRODUCTION AND LITERATURE REVIEW  
 Introduction 1 
 Rationale 4 
 Objectives of the study 5 
 General objective 5 
 Specific objectives 5 
 CHAPTER ONE  
 LITERATURE REVIEW 6 
1.1.  Historical background 6 
1.2.  Tuberculosis 8 
1.2.1.  Genetic susceptibility 10 
1.2.2. Etiology 11 
1.2.3.  Classification of the genus mycobacterium 12 
Please purchase PDFcamp Printer on http://www.verypdf.com/ to remove this watermark.
 XV
1.2.4.  Tuberculosis  14 
1.2. 4.1.  Signs and symptoms 14 
1.2. 4.2.  Transmission 14 
1.2. 4.3.  Prognosis of disease 16 
1.2. 4. 4.  Pathogenesis 16 
1.2. 5.  Immunity 18 
1.2. 6.  TB resumption  and risk factors 20 
1.2. 7.  Prevention 24 
1.2. 8.  Vaccine 25 
1.2. 9.  Mycobacterial cellular envelope 27 
1.2. 10   M. tuberculosis latency and reactivation 29 
1.2. 11.   Other causative agents of tuberculosis 30 
1.2. 11 .1. Mycobacteria other than tuberculosis (MOTT) 31 
1.3   Human immunodeficiency virus (HIV) 31 
1.3.1.  Mycobacterium tuberculosis-HIV Co-infection 32 
1.4.  Epidemiology of tuberculosis 39 
1.4.1.  Burden of TB in Sudan 41 
1.5.  M. tuberculosis genome 43 
1.6.   Diagnosis 44 
1.6.1.  Methods for the diagnosis of tuberculosis 46 
1.6.1.1.  A-conventional approaches 46 
1.6.1.1.1.  Microscopical diagnosis 46 
1.6.1.1.2  Culture and morphological characteristic 46  
Please purchase PDFcamp Printer on http://www.verypdf.com/ to remove this watermark.
 XVI
1.6.2.  The  identification of Mycobacteria 47 
1.7.  Drug Sensitivity Testing 48 
1.7.1.  Proportion method 48 
1.7.2.  Molecular methods 48 
1.7.2 .1.  Nucleic acid amplification testing 49  
1.7.2.1.1.  Simplified multiplex PCR assay 49 
1.7.2.1.2.  Single tube multiplex-PCR 50 
1.7.2.1.3. Multiplex allele specific PCR (MAS-PCR) 51 
1.7.3.  Genotyping of M. tuberculosis: Current Methods 52 
1.7.3.1. IS6110 RFLP  52 
1.7.3.2.  Spoligotyping 53 
1.7.3 .3.  MIRU-VNTR (12 loci) 53 
1.7.3 .4.  MIRU-VNTR (15 loci)  53 
1.8. Chemotherapy of tuberculosis 53 
1.9.  Drug resistance tuberculosis 55 
1.9.1. Molecular drug resistance tuberculosis 56  
1.9 .1.1.  Rifampin  58  
1.9 .1.2.  Isoniazid 59 
1.9.1.3.  Streptomycin 60  
1.9 .1.4.  Ethamutol 61  
1.9 .1.5.  Pyrazinamide 63 
1.9 .1.6.  Fluoroquinolones 63  
1.9 .1.7.  Cycloserine 64 
Please purchase PDFcamp Printer on http://www.verypdf.com/ to remove this watermark.
 XVII
1.10.  Treatment and chemotherapy 64 
CHAPTER TWO : MATERIALS AND METHODS 68 
2.1.  Study area 68 
2.2.  Study subjects 68 
2.2.1. Inclusion criteria 68 
2.2.2. Exclusion criteria 68 
2.3.  Study design 68 
2.4.  Sample size 68 
2.5. Sampling procedure 68 
2.6.  Demographic data 69 
2.7.  Laboratory investigation 69 
2.7.1.  Microscopical examination 70 
2.7.1.1. Direct Ziehl-Neelsen Stain 70 
2.7.2.  Isolation of M. tuberculosis 70 
2.7.2.1  Decontamination and inoculation of Specimen 70 
2.7.2.2  Examination schedule 71 
2.7.2.3.  Reading of cultures 71 
2.7.2.4.  Isolation and Preservation Techniques 72 
2.7.2.4.1.  Isolation 72 
2.7.2.4.2.  Preservation 72 
2.8.  Identification 72 
2.8.1. Primary Identification 72 
2.8.1.1.  Growth Rate 72 
Please purchase PDFcamp Printer on http://www.verypdf.com/ to remove this watermark.
 XVIII
2.8.1.2. Colonial morphology  73 
2.8.1.2.  Pigment Production 73 
2.8.2.  Biochemical Test 73 
2.8.2.1.  Catalase Test 73 
2.8.2.2.  Heat Stable Catalase Test at (pH7/680C)  73 
2.8.2.3.  Nitrate Reduction Test 74 
2.8.2.4.  Para Nitro-benzoic Acid (PNB) 500mg/l Susceptibility Test 74 
2.8.2.5. Thiophen-2-carboxylic Acid Hydrazide (TCH) 5ug/ml 
Susceptibility Test 
74 
2.9.  Susceptibility testing for Mycobacterium tuberculosis 75 
2.9.1  Preparation of Stock Solutions for Drugs 76 
2.9.1.1.  Isoniazid 76 
2.9.1.2.  Rifampicin 76 
2.9.1.3.  Dihydro-Streptomycin Sulfate 76 
2.9.1.4.  Ethambutol 76 
2.9.2  Preparation of Drug Containing Media 77 
2.9.2.1.  PNB  77 
2.9.2.2.  TCH 77 
2.9.3. Quality Control of Prepared Media 77 
2.9.4.  Preparation of Bacillary Suspension 78 
2.9.5.  Preparation of McFarland Solution 78 
2.10.  Molecular analysis 78 
2.10.1.  DNA extraction 78 
Please purchase PDFcamp Printer on http://www.verypdf.com/ to remove this watermark.
 XIX
2.10.2. Duplex polymerase chain assay (DPCR)  79 
2.10.2.1.  Procedure 80 
 2.10.3.  Multiplex PCR assay 80 
 2.10.3.1. Procedure  80 
2.10.4.  Molecular detection of  drug resistance 81 
 2.10.4.1.  Multiplex allele-specific PCR(MAS-PCR) 81 
2.11. HIV Diagnosis 83 
2.11.1.  Procedure 83 
2.11.1.1.  Genscreen ULTRA HIV Ag-Ab 83 
2.11.1.2. Calculation and Interpretation of the Results 85 
2.11.1.2.1. calculate the mean absorbance of the negative control 85 
2.11.1.2.2. Calculate the cut off value  86 
2.11.1.2.3. Assay validation 85 
2.11.1.2.4. Interpretation of the results 86 
2.11.1.2. Vironostika HIV Ag/Ab 87 
2.11.1.2.1. Results 89 
2.11.1.2.1.1. Manual calculation 88 
2.11.1.2.1.2. Qualification of the NC values 89 
2.11.1.2.1.3. Assay validity 89 
2.11.1.2.1.4. Cut-off value 89 
2.11.1.2.1.5. Interpretation of results 89 
2.12.  Statistical analysis 90 
CHAPTER THREE: RESULTS 91 
Please purchase PDFcamp Printer on http://www.verypdf.com/ to remove this watermark.
 XX
3.1.  Study population  91 
3.2.  HIV status among tuberculosis patients 91 
3.3.  Epidemiological data of the study subjects 91 
3.3.1. Age groups 91 
3.3.1.1.  Age and HIV 91 
3.3.2. Gender 91 
3.3.2.1. Gender and HIV status 92 
3.3.3. Infection among smoker  and alcoholic drinker 92 
3.3.4.  Marital status among the study population 92 
3.3.4.1. Marital status and HIV status 92 
3.3.5.  Residence 92 
3.3.6. Tribes according to the area of origin 92 
3.3.7. Educational level  93 
3.3.8. Occupation 93 
3.4. Clinical symptoms 93 
3.5. Microscopical examination 94 
3.6. Culture on LJ medium 94 
3.7. Biochemical Analysis 94 
3.7.1. Susceptibility testing to PNB and TCH 94 
3.7.2. Catalase test at 68oC 94 
3.7.3.  Nitrate reduction test 95 
3.8.  Molecular identification 95 
3.8.1. HIV and type of growth 95 
Please purchase PDFcamp Printer on http://www.verypdf.com/ to remove this watermark.
 XXI
3.9. Drug susceptibility 95 
3.9.1. HIV and Drug resistance 96 
3.10. MAS-PCR 96 
3.10.1. Sensitivity and specificity 97 
CHAPTER FOUR: DISCUSSION 114 
 Discussion 114 
 Conclusions 122 
 Recommendations  123 
 REFRENCES 124 
 Appendix  
 
Please purchase PDFcamp Printer on http://www.verypdf.com/ to remove this watermark.
 XXII
List of Figures 
 
   
Fig 1 HIV status among Tuberculosis patients 99 
Fig 2 Distribution of pulmonary tuberculosis in different age 
group 
100 
  
Fig 3 Distribution of marital status among pulmonary tubercles 
patients 
101 
Fig 4 Distribution of pulmonary tuberculosis according to the Area 
of origin 
102 
Fig 5 Distribution of pulmonary tuberculosis according to 
education level 
103 
Fig 6 Results of differentiation of Mycobacterium tuberculosis 
complexand Non Mycobacterium tuberculosisby a singletube 
Duplex-PCR 
104 
Fig 7 Results of differentiation of Mycobacterium bovisand 
Mycobacterium  tuberculosisby a singletube multiplex-PCR 
105 
Fig 8 Results of Drug Susceptibility testing 106 
Fig 9 Results of MAS-PCR 107 
Fig 10 The frequency of banding patterns illustrate the mutant 
genes 
108 
 
Please purchase PDFcamp Printer on http://www.verypdf.com/ to remove this watermark.
 XXIII
 
List of Tables 
 
Table 1: 
Primers for MAS-PCR to detect INH, RIF, and EMB 
resistance mutations of M. tuberculosis 
82 
Table 2 Age group and HIV status 109 
Table 3 marital status and HIV status 110 
Table 4 Type of growth and HIV status 110 
Table 5 
Patterns of drug resistance of the studied 
mycobacterium isolates 
111 
Table 6 Drug resistance and H IV status 112 
Table 7 
 
 
 
 
 
 
 
Comparison between conventional drug susceptibility 
testing and MAS-PCR (concordant and discordant and 
the genes associated to MAS-PCR) and sensitivity and 
specificity of MAS-PCR 
113 
   
   
 
Please purchase PDFcamp Printer on http://www.verypdf.com/ to remove this watermark.
 1
INTRODUCTION  
Tuberculosis (TB) is an important public health problem worldwide due to 
AIDS epidemic, (Souza 2006). In the last decade, TB has reemerged as one of 
the leading causes of death with nearly 3 million deaths annually (Bloom and 
Murray 1992). These death rates, however, only partially depict the global TB 
threat; more than 80% of TB patients are in the economically productive age of 
15 to 49 years. The emergence of AIDS and decline of socioeconomic 
standards contribute to the disease’s resurgence in industrialized countries 
(Rattan et al 1998). According to World Health Organization (WHO), which 
declared tuberculosis a global health emergency in 1993, tuberculosis, without 
a coordinated control effort, will infect an estimated 1 billion people by 2020, 
killing 70 million (Souza 2006). This contagious disease is transmitted through 
the air and it is caused by the bacterium Mycobacterium tuberculosis, which 
can attack different organs of human body. However, it most commonly affects 
the lungs, which is responsible for more than 75 percent of cases. Factors 
which responsible for the resurgence of TB, are people infected with HIV 
virus, immigration, war, famine, homelessness, the lack of new drugs and 
multi-drug-resistant tuberculosis (MDR TB) due to inconsistent or partial 
treatment (Souza 2006). Resistance to antituberculous drugs is an emerging 
global health problem (Ariel pablos- Mendez et al 1998). 
The global distribution of TB cases is skewed heavily toward low-income and 
emerging economies. The highest prevalence of cases is in Asia, where China, 
India, Bangladesh, Indonesia, and Pakistan collectively make up over 50% of 
the global burden. Africa, and more specifically sub-Saharan Africa, have the 
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highest incidence rate of TB, with approximately 83 and 290 per 100,000, 
respectively (Dye et al 1999). 
As more countries implement MDR-TB treatment programs, greater is the need 
for effective methods to identify MDR strains rapidly. Although several rapid 
phenotypic methods offer promise, genotypic testing based on the 
identification of mutations conferring resistance to rifampcin (RIF) is the most 
rapid method available to date. Given that 90% of M. tuberculosis isolates 
resistant to RIF are also resistant to isoniazid, (Shin et al 2005), the 
confirmation of RIF resistance provides an effective screening tool for the 
identification of MDR strains. Characterization of the rpoB gene has resulted in 
the identification of mutations conferring resistance to RIF (Ramaswamy and 
Musser 1998). It is estimated that approximately 96% of mutations responsible 
for conferring RIF resistance are single amino acid substitutions in the 81 -bp 
core region of the rpoB gene, which encodes the subunit of RNA polymerase 
(Iseman 1993). 
Yang et al (2005) developed a multiplex allele-specific polymerase chain 
reaction (MAS-PCR) that detects the most commonly observed isoniazid 
(INH), rifampcin (RIF), and ethambutol resistance-associated mutations in a 
single assay. Distinct PCR banding patterns were observed for different 
mutation profiles and the correlation between MAS-PCR results and DNA 
sequencing findings was 99.4%. With culture-based phenotypic drug 
susceptibility testing as a reference standard, the sensitivity and specificity of 
the newly developed MAS-PCR assay for drug resistance-related genetic 
mutation detection were high, except for ethambutol (EMB). MAS-PCR 
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provides a rapid, potentially more cost-effective, method of detecting 
multidrug-resistant TB (Yang et al 2005). Genetic markers of resistance to 
isoniazid (INH) and rifampcin (RIF) have been identified (Makinen 2006). For 
INH, two genes including the catalase-peroxidase (KatG) and the enoyl acyl 
reductase gene inhA, have been reported (Musser 1995, Hillemann 2005). For 
RIF, the ß  subunit of RNA polymerase, rpoB, appears to be the major 
determinant of resistance (Hillemann 2005). Two genes rpsL and rrs, were 
associated with ribosomal resistance to streptomycin (SM), (Nachmakin et al 
1997). 
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RATIONALE 
 
Laboratory methods play crucial role in establishing the diagnosis, monitoring 
therapy, and prevention of tuberculosis. 
There is a great need to determine the situation of HIV/ AIDS among TB co-
infection in Sudan because Sudan is a TB endemic country and also is among 
the Sub-Sahara African countries because tuberculosis is associated with 
human immunodeficiency virus (HIV) infection. HIV is known to increase the 
risk of tuberculosis infection especially among multidrug resistant (MDR) and 
reactivate dormant tuberculosis. 
The need for rapid and specific test for the identification of Mycobacteria other 
than M. tuberculosis is essential for an effective treatment and control of the 
disease. Very few studies had been done in the area. According to many studies 
on some assays of new technology, the later are not capable of replacing the 
traditional methods of conventional susceptibility testing for M. tuberculosis. 
The rapid development and availability of a variety of new molecular genetic 
technologies present in the clinic are array of options for the accurate diagnosis 
of infectious diseases. This is particular in case of tuberculosis. Molecular 
techniques used as a diagnostic tool in tuberculosis, though it is rapid and 
sensitive but yet their clinical validity remains controversial and consequently, 
the application of gene amplification to routine diagnosis of tuberculosis is 
important and need to be studied. 
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OBJECTIVES   
 
General objective: 
· To detect the drug resistance patterns of M. tuberculosis strains to 1st 
line anti-tuberculosis drug. 
· To determine the frequency of HIV positive among TB patients. 
 
Specific objectives: 
1. To determine the situation of anti-HIV antibodies among TB patients. 
2. To identify the strains of Mycobacteria isolated from patients. 
3. To determine the situation of multi-drug resistant strains of M.TB. 
4. To characterize the multi-drug resistance in strains of M.TB using 
molecular techniques. 
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CHAPTER ONE 
LITERATURE REVIEW 
 
1.1. Historical background 
Tuberculosis became the principal cause of death by the end of the nineteenth 
century and the beginning of the 20th century. Although it was probably 
described for the first time in Indian texts, pulmonary TB is known since the 
time of Hippocrates as phthisis, which is derived from the Greek for wasting 
away. It was well documented during the European Middle Age, when it was 
believed that cure resulted from the power of the divine touch of the kings 
(Ducati et al 2006). In 1680, the French, Franciscus Sylvius carried out 
anatomic-pathologic studies in pulmonary nodules from TB patients, that he 
named as tubercula (small knots), observing their evolution to lung ulcers 
(cavities). However, most of the great pathologists of his time believed these 
knots were some type of tumor or abnormal glands, rejecting any probable 
infectious origin. The first credible speculation of the infectious nature of TB 
was performed by the British Doctor Benjamin Marten, who proposed in 1722, 
that TB could be transmitted through the breath of a sick person, inhaled by a 
sound one, and thereby turning him ill (Ducati et al 2006). 
One of the greatest works on TB was performed in 1882 by Robert Koch, an 
esteemed scientist at his time; Koch isolated and cultured M. tuberculosis from 
crushed tubercles. His experimental work identified the bacterium as the TB 
etiological agent (Bloom and Murray 1992, Daniel 1997). The tuberculin skin 
test became the principal tool for diagnosing TB infection up to date. In the 
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same period, Koch developed staining methods for the identification of the 
bacillus; these techniques were subsequently improved by the German Doctor 
and bacteriologist Paul Ehrlich, whose method for detection of the bacillus 
provided the basis for the development of the Ziehl-Nielsen staining procedure, 
which was still important for diagnosis of TB (Ducati et al 2006). 
Previously, in the classic period of the Roman Empire, Clarissimus Galenus, 
son of the great mathematician and architect Nikon, used to prescribe to his 
patients treatments based on fresh milk, pure air, maritime trips, horseback 
rides, and much rest in dry environments of higher altitude. TB treatment has 
evolved throughout time, from magical potions to rational drug use (Daniel, 
1997). Koch’s discovery allowed researchers to focus efforts on the 
development of new and more efficient therapies to treat TB patients. One of 
the first attempts to fight the disease was performed by Edward Livingston 
Trudeau, who suffered from TB and was subsequently cured. Trudeau 
established the first sanatorium in the United States in 1884. This institution 
received only TB patients, and invested in a treatment based on rest, fresh air 
and healthy diet (Ducati et al 2006). 
in 1896, the American bacteriologist Theobald Smith demonstrated that bovine 
TB was not caused by M. tuberculosis, but rather by another species, M. bovis. 
Twelve years later, the scientists-couple Albert Calmette and Camille Guérin 
isolated the bovine variant from its host and grew the bacilli in dispersed 
culture containing ox bile. 
The introduction of antibiotics, such as streptomycin (1947), isoniazid 
(synthesized in 1912, but introduced 40 years later) and p-aminosalicylic acid, 
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led to a TB chemotherapy revolution, as TB mortality rates were considerably 
reduced (Bloom and Murray 1992, Daniel 1997). Subsequently, other anti-PB 
drugs were also developed, such as ethambutol 
and rifampcin among others. Since the mid 1980s, however, there has been no 
new first line drug development to fight the TB causing bacilli (Petrini and 
Hoffner 1999). 
By the late 1 960s, tuberculosis had become an infectious disease that could be 
successfully treated and cured with antibiotics in all industrialized countries, 
the development of new drugs was no longer compelling. The situation was 
different, however, in developing countries, where TB remained widespread 
due to poor sanitation and public health conditions could not be fought 
aggressively due to the lack of sufficient resources. As a result, these countries 
became the “reservoir” of a very large population of contagious patients 
(Grassi and Poona 1995). 
From the late 1980s, tuberculosis has again become a problem throughout the 
world, due to the increasing migration from developing countries and the 
spread of the human immunodeficiency virus (HIV) infection. In this context, 
the spread of drug resistant M. tuberculosis strains, both in developing 
countries and in large urban areas of industrialized countries, has made the 
classic armamentarium of anti-tuberculous drugs insufficient and thus, the 
research for new drugs again became a world public health priority. 
1.2. Tuberculosis 
Tuberculosis is localized primarily in the lungs, the main lesion being the 
pulmonary cavity, which contains about 108 mycobacteria (= l08 cfu) (Canetti, 
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1959). Among these organisms, which are normally drug sensitive, there are 
drug resistance mutants at a mean frequency of = 10-6 (Canetti, and Grosset, 
1961). In the pulmonary cavity, a large bacillary population is located in the 
thin liquid caseous layer that covers the inner part of the cavity wall. These 
bacilli are extracellular and multiply actively because of the favourable oxygen 
tension and nutritive substances found in the cavity. In addition to the large 
population in the cavity, one inside macrophage and another inside solid 
caseous foci (Grosset 1980). 
Tuberculosis is on increase throughout the world (CDC 1993), and remains as 
one of the few infections whose diagnosis often relies on clinical acumen. The 
reasons for this are manifold, microscopic examination with either Ziehi-
Neelsen (ZN) or fluorochrome stained smears is insensitive, detecting acid-fast 
bacilli only when there are ³104 mycobacteria per ml. Culture on solid medium 
is labor-intensive and too slow for clinical usefulness, taking a minimum of 2 
weeks and often longer for microscopy-negative samples. Radiometric liquid 
(BACTEC) and biphasic (MB Chek) culture systems have improved both the 
recovery rates and the speed of isolation, but these systems still cannot 
influence decision making (Ichiyama et al 1993, Isenberg et al 1991). Given 
that half of estimated 8 million new cases of TB per year is either smear -
negative pulmonary or extrapulmonary infection (Styblo and Rouillon 1981). 
Like many other infectious diseases, TB presents epidemic cycles that might, 
although rarely, take centuries to end its course. History has proved that 
pathogenic virulence suffers considerable reduction along time, and natural 
selection takes place upon its hosts, as only the more genetically resistant ones 
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survive. Since untreated TB patients have mortality rates ranging from 40 to 
60%, one can consider the possibility of human selection occurrence in favor to 
the ones with increased genetic resistance (Bloom and Small 1998). Although 
genes will not influence the risk of infection upon exposure, they might 
determine the risk of disease development and its course (Daniel 1997). 
1.2.1. Genetic susceptibility 
Although genetic variability evidence on TB human susceptibility is very 
difficult to be determined, several studies revealed a greater disease severity 
among black than white people, there is a greater TB course agreement 
between monozygotic than heterozygotic twins, and populations more recently 
exposed to the TB bacillus have a greater propensity to develop the disease 
when compared to others that coexist with TB for centuries. As one gathers all 
these data, he can suppose that M. tuberculosis still is an extraordinary 
pathogen that exerts a powerful selective pressure on the human genome 
(Bloom and Small 1998). Previous studies have reported that the CD209 
promoter single nucleotide polymorphism (SNP)-336A/G exerts an effect on 
CD209 expression and is associated with human susceptibility to dengue, HIV-
1 and tuberculosis in humans. The study by Vannberg et al (2008), investigate 
the role of the CD209- 336A/G variant in susceptibility to tuberculosis in a 
large sample of individuals from sub-Saharan Africa. Significant overall 
protection against pulmonary tuberculosis was observed with the -336G allele 
when the study groups were combined .In addition, the patients with -336GG 
were associated with a decreased risk of cavitory tuberculosis, a severe form of 
tuberculosis disease (P = 0.00003), This direction of association is opposite to 
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a previously observed result in a smaller study of susceptibility to tuberculosis 
in a South African Coloured population, but entirely in keeping with the 
previously observed protective effect of the -336G allele (Vannberg et al 
2008). 
1.2.2. Etiology 
Mycobacterium tuberculosis is the principal TB etiological agent in humans; it 
is a weak Gram-positive rod-shaped bacterium that has no flagellum, does not 
form spores nor produces toxins and has no capsule. The microbe’s width and 
height vary from 0.3 to 0.6 and 1 to 4 mm, respectively, and it presents a 
complex cellular envelope, considerably slow in growth, and genetic 
homogeneity. 
It is a macrophage intracellular pathogen that establishes its infection 
preferentially in the pulmonary system, where it is usually conditioned into a 
dormant state as long as host’s immune system prevails. The generation time 
was around 24 h in both synthetic medium and on infected animals (Cole et al 
1998). Bacterial growth in laboratory environment permits visual colony 
formation; these have dry and wrinkled surfaces, and require 3 to 4 weeks of 
growth on solid media to become visible (Bloom and Murray 1992). Owing to 
its pathogenicity and aerosol transmission, there are specific biosafety 
guidelines that demand the use of laminar-flow hoods and level 3 facility 
equipments for M. tuberculosis laboratorial work. Currently, there are more 
than 100 known mycobacteria species, most of them being saprophytic soil 
bacteria; and a minority of these species is pathogenic to humans, causing TB 
(M. tuberculosis, M. bovis, and M. africanum) and leprosy (M. leprae) (Jarlier 
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and Nikaido, 1994). The M. tuberculosis complex consists of M. tuberculosis, 
M bovis, M bovis BCG, M. africanum, and M. microti; and it is believed that 
.their ancestral is a bacterium from soil, and that the human bacillus may have 
been derived from the bovine form (M. bovis), probably through cattle 
domestication by the pre-dynastic Egyptians (Daniel, 1997). 
M. tuberculosis genomic studies indicate that horizontal transference of genetic 
material to a free living ancestral from the M. tuberculosis complex might have 
occurred in nature before the bacillus adopted its specialized intracellular niche 
(Cole et al 1998, Daniel 1997). There is a great variability in the infection rates 
among people exposed to different infection sources, and among infected ones, 
approximately 90% will never develop the disease at all. There are also 
differences in the capability to transmit the infection among patients due to 
exhaled bacterial charge variability. Experimental evidences also suggested 
that, the observed variation in transmission potential might be attributed to 
pathogenic features. M. tuberculosis can have virulence variations among 
different strains; the more virulent ones present higher pathogenicity or 
capacity to develop active disease. However, it should be pointed out that it is 
fundamental to have a clear distinction between the capacity a strain has to 
cause infection and its capacity to develop the disease (Bloom and Small 
1998). 
1.2.3. Classification of the genus Mycobacterium 
The classification of mycobacteria began in 1896 when Lehmann and 
Neumann (Lehmann et al 1896) proposed the genus Mycobacterium to include 
these species (renamed Mycobacterium tuberculosis and Mycobacterium 
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lepare).The genus was placed in the Mycobacteriaceae family, 
Actinomycetales order and Actinomycetes class (Shinnick and Good 1994). 
In 2004, Ryan and Ray classified M. tuberculosis as follows: 
Kingdom: Bacteria, Phylum: Actinobacteria, Order: Actinomycetales, 
Suborder: Corynebacterineae, Family: Mycobacteriaceae, Genus: 
Mycobacterium and Species: M. tuberculosis. In 2005, the different types of 
mycobacteria were also classified according to their pathogenesis to: (a) 
Fraction pathogen (b) Often pathogen(c) Potential /Rare pathogen (d) Usual 
saprophyte-Rare pathogen (Sanusi 2005). 
A fundamental taxonomic division of mycobacteria was based on growth rate 
and pigmentation. By these criteria, the genus Mycobacterium has been divided 
into four Runyon groups: group I, the photochromogenic species of slow 
growers; group II, the scotochromogenic species of slow growers; group III, 
the nonphotochromogenic species of slow growers; and group IV, the rapid 
growers (Runyon, 1959; Runyon, 1970). Further attempts to subdivide the 
mycobacterial species have been made using immunological techniques 
(Tuboly, 1965), comparison of cell wall components (Minnikin, et al 1984), 
and DNA-DNA hybridization (Imaeda et al 1988, Baess 1982, Baess, 1979 
Gross, and Wayne, 1970), but these taxonomic reports provide only little 
phylogenetic information. Recently, the nucleotide sequence comparison of the 
16s rRNA genes, was systematically used to infer phylogenetic relationships 
among the mycobacteria (Pitulle et al 1992, Rogall et al 1990, Stahl, and 
Urbance 1990). 
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1.2.4. Tuberculosis 
1.2. 4.1. Signs and symptoms 
When the disease becomes active, 75% of the cases are pulmonary TB. 
Symptoms in this case include chest pain, coughing up blood, and a productive, 
prolonged cough for more than two weeks. Systemic symptoms include fever, 
chills, night sweats, appetite loss, weight loss, paleness, and often a tendency to 
fatigue very easily (WHO, 2007). In the other 25% of active cases, the 
infection moves from lungs, causing other kinds of TB, collectively denoted 
extrapulmonary tuberculosis (Kiblawi et al 1981). This occurs more commonly 
in immunosuppressed persons and young children. Infection of other organs 
causes a wide range of symptoms. Extrapulmonary infection sites include the 
pleura in tuberculosis pleurisy, the central nervous system in meningitis, and 
the lymphatic system in scrofula of the neck, the genitourinary system in 
urogenital tuberculosis, and bones and joints in Pott’s disease of the spine. An 
especially serious form is disseminated TB, more commonly known as milliary 
tuberculosis. Extrapulmonary TB may co-exist with pulmonary TB as well 
(CDC 2000). 
1.2.4.2. Transmission 
Active TB patients usually cough, as a result of typical chronic pulmonary 
inflammation. This constitutes the main dissemination mechanism for the 
pathogen to new hosts (Glickman and Jacobs  2001). The released particles 
from an ill patient are exhaled from the infected lungs into the air, being able to 
remain in suspension for hours, representing a highly contagious disease (NSB 
Editorial Comment 2000), due to their waxy coats, which limit fluid loss across 
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the cell membrane M. tuberculosis, remain viable much longer than most other 
bacteria in an airborne or exposed state (Iseman 2000). In addition, the small 
size of the bacteria (l-4um in length and 0.3-0.6 urn in diameter) may also 
prolong the aerosols circulation time (Iseman 2000). Infection usually occurs 
from person to person through the inhalation of the infective particles 
(Pasqualoto and Ferreira 2001). Experiments with animal models demonstrate 
that particles in suspension containing 1 to 10 bacilli are enough to cause an 
infection. The main determinants of risk of infection are the concentration of 
bacilli in an exhaled particle from a source, its aerodynamic features, the 
ventilation rate, and the exposure period (Bloom and Murray 1992). When 
people suffering from active pulmonary TB coughs, sneeze, speak, or spit, they 
expel infectious aerosol droplets 0.5 to 5 mm in diameter. A single sneeze can 
release up to 40,000 droplets (Cole and Cook 1998). Each one of these droplets 
may transmit the disease, since the infectious dose of tuberculosis is very low 
and inhaling less than ten bacteria may cause an infection (Nicas  et al 2005 
and Behr et al 1999). Transmission can only occur from people with active -not 
latent TB (Vinay et al 2007). The probability of transmission from one person 
to another depends upon the number of infectious droplets expelled by a 
carrier, the effectiveness of ventilation, the duration of exposure, and the 
virulence of the M. tuberculosis strain (CDC 2000). The chain of transmission 
can, therefore, be broken by isolating patients with active disease and starting 
effective anti-tuberculous therapy. After two weeks of such treatment, people 
with non-resistant active TB generally cease to be contagious. The amount of 
contact necessary for TB infection to be transmitted is variable and depends on 
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the infectiousness of the source case and the environment in which the contact 
occurs. In general, laryngeal TB and pulmonary TB, particularly cavitary 
pulmonary TB, are considered the most infectious forms of the disease 
(Lincoln, 1965). The environment in which the contact occurs is also important 
in assessing infectiousness. Transmission is rarely thought to occur outdoors; 
however, indoor environments that are poorly ventilated, dark and damp can 
lead to increased concentration and survival of Mycobacterium tuberculosis 
(Riley, 1957 and Nardell 1999). 
1.2.4.3. Prognosis of disease 
Progression from TB infection to TB disease occurs when the TB bacilli 
overcome the immune system defenses and begin to multiply. In primary TB 
disease 1-5% of cases, this occurs soon after infection (Vinay et al 2007). 
However, in the majority of cases, a latent infection occurs that has no obvious 
symptoms (Vinay et al 2007). These dormant bacilli can produce tuberculosis 
in 2-23% of these latent cases, often many years after infection (Parrish et al 
1998). The risk of reactivation increases with immunosuppressive conditions, 
such as that caused by co-infection with HIV. Since it was reported that, the 
risk of reactivation increases 10% per year (Phillip and Graham 2004; Vinay et 
al 2007). 
1.2.4.4. Pathogenesis 
About 90% of those infected with Mycobacterium tuberculosis have 
asymptomatic, latent TB infection (sometimes called LTBI), with only a 10% 
lifetime chance that a latent infection will progress to active TB disease (Vinay 
et al 2007). However, if untreated, the death rate for these active TB cases is 
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more than 50% (Phillip and Graham 2004). TB infection begins when the 
mycobacteria reach the pulmonary alveoli, where they invade and replicate 
within the endosomes of alveolar macrophages (Vinay et al 2007, Houben et al 
2006). The primary site of infection in the lungs is called the Ghon focus, and 
is generally located in either the upper part of the lower lobe, or the, lower part 
of the upper lobe (Vinay et al 2007). Bacteria are picked up by dendritic cells, 
which do not allow replication, although these cells can transport the bacilli to 
local (mediastinal) lymph nodes. Further spread is through the bloodstream to 
other tissues and organs where secondary TB lesions can develop in other parts 
of the lung (particularly the apex of the upper lobes). Peripheral lymph nodes, 
kidneys, brain, and bone (Vinay et al 2007, Herrmann and Lagrange 2005). All 
parts of the body can be affected by the disease, though it rarely affects the 
heart, skeletal muscles, pancreas and thyroid (Agarwal et al 2005). 
Tuberculosis is classified as one of the granulomatous inflammatory 
conditions. Macrophages, T lymphocytes, B lymphocytes and fibroblasts are 
among the cells that aggregate to form a granuloma, with lymphocytes 
surrounding the infected macrophages. The granuloma functions not only to 
prevent dissemination of the mycobacteria, but also provides a local 
environment for communication of cells of the immune system. Within the 
granuloma, T lymphocytes secrete cytokines such as interferon gamma, which 
activates macrophages to destroy the bacteria with which they are infected 
(Kaufmann 2002). Cytotoxic T cells can also directly kill infected cells, by 
secreting perforin and granulysin (Houben et al 2006). Importantly, bacteria 
are not always eliminated within the granuloma, but can become dormant, 
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resulting in a latent infection (Vinay et al 2007). Another feature of the 
granulomas of human tuberculosis is the development of abnormal cell death, 
also called necrosis, in the center of tubercles. To the naked eye this has the 
texture of soft white cheese and was termed caseous necrosis (Grosset 2003). If 
TB bacteria gain entry to the bloodstream from an area of damaged tissue they 
spread through the body and set up many foci of infection, all appearing as tiny 
white tubercles in the tissues. This severe form of TB disease is most common 
in infants and the elderly and is called milliary tuberculosis. Patients with this 
disseminated TB have a fatality rate near 100% if untreated. However, if 
treated early, the fatality rate is reduced to near 10% (Kim et al 2003). In many 
patients the infection waxes and wanes, Tissue destruction and necrosis are 
balanced by healing and fibrosis (Grosset 2003). Affected tissue is replaced by 
scarring and cavities filled with cheese-like white necrotic material. During 
active disease, some of these cavities are joined to the air passages bronchi and 
this material can be coughed up. It contains living bacteria and can therefore 
pass on infection. Treatment with appropriate antibiotics kills bacteria and 
allows healing to take place. Upon cure, affected areas are eventually replaced 
by scar tissue (Grosset 2003). If untreated, infection with Mycobacterium 
tuberculosis can become lobar pneumonia. (Sambandamurth et al 2002). 
1.2.5. Immunity: 
The immune response against tuberculosis (TB) plays a fundamental role in the 
outcome of M. tuberculosis infection. It is clear that the immune system reacts 
efficiently in the vast majority of infections. The risk of developing the disease 
increases considerably when TB infection co-exists with an alteration in the 
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immune system, such as co-infection with human immunodeficiency virus 
(HIV) (Arriaga et al 2002). 
TB bacilli usually multiply first in the lung alveoli and alveolar ducts and in 
draining lymph nodes, where they are engulfed by dendritic cells (DCs). They 
also multiply in the macrophages that were attracted from the bloodstream and 
are armed to kill the bacteria upon uptake in their phagosomes. Mycobacteria 
can evade the phagosome-lysosome fusion pathway, multiply in the host 
macrophages and kill them, creating a primary tubercle. The outcome of 
infection is controlled by CD4 and CD8 + T cells, both of which are necessary 
for the maintenance of a latent state of infection. Delayed cutaneous 
hypersensitivity develops and together with other cellular immune reactions, 
leads to the caseous necrosis of the primary complex. Bacilli eventually spread 
to many parts of the body such as liver, spleen, meninges, bones, kidneys and 
lymph nodes, where they can either be a source of overtly disseminated TB or, 
more commonly, remain dormant. 
Occasional decline in cell-mediated immunity leads to reactivation TB, most 
frequently seen in adults as a pulmonary disease with infiltration or cavity in 
the apex of the lung. This is the most common and most infectious form of TB. 
CD4+ T-cells play a major role in containment of TB infection; TB is usually 
associated with a Th2 T-cell response, whereas a pure Th1 response, including 
production of IL-2 and IFN-? , mediates protection. CD8+ T cells and 
macrophages are involved in the control of mycobacterial infection. The 
production of Th1 associated cytokines such as IFN-g, TNFa and IL-12 
appears to be an essential component of resistance to MTB infection. The most 
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effective vaccination strategies in animal models have been those that stimulate 
T cell responses, both CD4+ and CD8+, to produce these cytokines (Arriaga et 
al 2002). 
1.2.6. TB resumption and risk factors 
In 1993 the WHO declared TB a global public health emergency, being the 
only disease so far to warrant that designation. Although hospitals have been 
established and chemotherapy has been developed to combat TB, that have 
brought considerable reduction in incidence to developed nations, historical 
data calculated by the WHO indicated that there have not been great effects on 
the global problem since the time of Koch (Bloom and Murray 1992). 
TB resumption has been attributed to several factors, such as the increase in 
drug resistance; the HIV/AIDS pandemic (in the beginning of the 1980s); the 
increase of injectable drug users; changes in social structure; the increase of 
immigrants from high prevalence nations to developed ones; the aging of the 
world population; the active transmission amongst environments of human 
accumulation (such as prisons, hospitals, and homeless shelters); and the 
degradation of health care systems (Fätkenheuer et al 1999). 
In order to facilitate the comprehension of the various components involved in 
the interaction between these factors, Ruffino-Netto (2004) proposed an 
equation that expresses the TB charge, represented as follows: 
TbB » (SIN). (PHIV). (PDEF). (PR). (MIG). (OLDP)/(AHS). (DOTS). (EDU). 
(NUT). (HRTb). (DPP)  
where SIN: social inequality; PHIV: prevalence of HIV positive; PDEF: 
percentual default of treatment; PR: prevalence of primary resistance + 
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acquired resistance; MIG: migrations; OLDP: age of the population; AHS: 
adequate health services; DOTS: directly observed treatment short-course; 
EDU: educational level; NUT: nutrition level; HRTb: human resources for TB 
control; DPP: degree of political participation of the population. Among all the 
components, social inequality should be emphasized as the most important one, 
since it generates poverty and consequently leads to malnutrition, ill provided 
living conditions and education among others, thereby influencing practically 
all other components. It should also be pointed out that the prevalence of 
primary resistance stands as an aggravating epidemiological factor more 
important than acquired resistance. According to Ruffino-Netto (2004), the 
above mentioned expression does not represent a mathematical equation and, 
therefore, will not yield predictable numeric solutions, but rather facilitates to 
wonder about the problem (TB charge analysis). One should notice that it 
contains variables of qualitative nature. In countries such as India, China, 
Indonesia, Pakistan, Nigeria, Philippine, South Africa, Ethiopia, Vietnam, 
Russian Federation, Democratic Republic of Congo, Brazil, United Republic of 
Tanzania, Kenya, Thailand, Myanmar, Afghanistan, Uganda, Peru, Zimbabwe, 
and Cambodia, it is estimated an occurrence of up to 80% of world TB cases. It 
can be immediately perceived that, among the above-mentioned nations, the 
problem may be located either at the level of the numerator, denominator, or 
both within the expression. In Russia, for example, the multidrug-resistance 
prevalence problem is prominent and severe. In African nations, all the 
numerator and denominator components have a strong influence. Brazil might 
represent an intermediate condition, as it displays a (yet) small multidrug-
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resistance prevalence problem, but deals with major social inequality and has 
all remaining components in a phase of organization. People with prolonged, 
frequent, or intense contact are at particularly at high risk of becoming 
infected, with an estimated 22% infection rate. A person with active but 
untreated tuberculosis can infect about 10-15 other people per year (WHO 
2007).Others at risk include people in areas where TB is common, people who 
inject drugs using unsanitary needles, residents and employees of high-risk 
congregate settings, medically under-served and low-income populations, high-
risk racial or ethnic minority populations, children exposed to adults in high-
risk categories, patients immuno-compromised by conditions such as 
HIV/AIDS, people who take immunosuppressant drugs, and health care 
workers serving these high-risk clients (Griffith and Kerr 1996). Persons with 
silicosis have an approximately 30-fold greater risk for developing TB; Silica 
particles irritate the respiratory system, causing immunogenic responses such 
as phagocytosis that consequently results in high lymphatic vessel deposits 
(Lee 1948). It is this interference and blockage of macrophage function that 
increases the risk of tuberculosis. Persons with chronic renal failure who are on 
hemodialysis also have an increased risk: 10—25 times greater than the general 
population. Persons with diabetes mellitus have a risk for developing active TB 
that is two to four times greater than persons without diabetes mellitus, and this 
risk is likely to be greater in persons with insulin- dependent or poorly 
controlled diabetes. Other clinical conditions that have been associated with 
active TB include gastrectomy with attendant weight loss and malabsorption, 
jejunoileal bypass, renal and cardiac transplantation, carcinoma of the head or 
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neck, and other neoplasms (e.g., lung cancer, lymphoma, and leukemia, (CDC 
2010). 
Given that silicosis greatly increases the risk of tuberculosis, more research 
about the effect of various (indoor) air pollutants on the disease would be 
necessary. Some possible indoor source of silica includes paints, concrete and 
Portland cement. Crystalline silica is found in concrete, masonry, sandstone, 
rock, paints, and other abrasives. The cutting, breaking, crushing, drilling, 
grinding or abrasive blasting of these materials may produce fine silica dust. It 
can also be in soil, mortar, plaster, and shingles. When you wear dusty clothing 
at home or in your car, you may be carrying silica dust that your family will 
breathe, (CDC 2010). 
Low body weight is associated with risk of tuberculosis as well. A body mass 
index (BMI) below 18.5 increases the risk by 2-3 times. On the other hand, an 
increase in body weight lowers the risk. (Leung et al 2010). Patients with 
diabetes mellitus are at increased risk of contracting tuberculosis (Restrepo 
2007), and they have a poorer response to treatment, possibly due to poorer 
drug absorption (Nijland et al 2006). 
Other conditions that increase risk include IV drug abuse; recent TB infection 
or a history of inadequately treated TB; chest X-ray suggestive of previous TB, 
showing fibrotic lesions and nodules; prolonged corticosteroid therapy and 
other immunosuppressive therapy; Immunocompromised patients (30-40% of 
AIDS patients in the world also have TB) hematologic and reticuloendothelial 
diseases, such as leukemia and Hodgkin’s disease; end-stage kidney disease; 
intestinal bypass; chronic malabsorption syndromes; vitamin D deficiency 
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(Nnoaham and Clarke  2008), and low body weight ((Vinay et al 2007 ,CDC 
2000). Twin studies in the 1940s showed that susceptibility to TB was 
heritable. If one of a pair of twins got TB, then the other was more likely to get 
TB if he was identical than if he was not (Kallmann and Reisner 1942). These 
findings were more recently confirmed by a series of studies in South Africa 
(Jepson et al 2001; Sepulveda et al 1994, Cobat et al 2010). Specific gene 
polymorphisms in IL12B has been linked to tuberculosis susceptibility (Tso et 
al 2004). Some drugs including rheumatoid arthritis drugs that work by 
blocking tumor necrosis factor-alpha (an inflammation-causing cytokine), raise 
the risk of activating a latent infection due to the importance of this cytokine in 
the immune defense against TB (Mutlu et al 2006). 
1.2.7. Prevention: 
TB prevention and control takes two parallel approaches. In the first, people 
with TB and their contacts are identified and then treated. Identification of 
infections often involves testing high-risk groups for TB. In the second 
approach, children are vaccinated to protect them from TB. No vaccine is 
available that provides reliable protection for adults. However, in tropical areas 
where the levels of other species of mycobacteria are high, exposure to non 
tuberculous mycobacteria gives some protection against TB (Fine et al 2001). 
The World Health Organization (WHO) declared TB a global health 
emergency in 1993, and the Stop TB Partnership developed a Global Plan to 
Stop Tuberculosis that aims to save 14 million lives between 2006 and 2015 
(WHO 2006a). Since humans are the only host of Mycobacterium tuberculosis, 
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eradication would be possible. This goal would be helped greatly by an 
effective vaccine (Martin 2006). 
1.2.7.1. Biosafety and Health control 
Compared with the general population, laboratory personnel have a three to 
nine times greater risk of acquiring latent TB infection, Collins and Kennedy, 
(1998), compliance with biosafety practices as outlined in the Laboratory 
Biosafety Guidelines and other standards for working with cultures of MTBC 
is critical ( Richmond  et al 1996, Heifets and Desmond 2005). 
Individuals who work in mycobacterial laboratories: 
· Should have an annual large-film chest X-ray and medical examination. 
· Should preferably have a positive Mantoux test (5TU) or provide 
evidence of vaccination with BCG. 
· Should record all laboratory accidents and report them to the Safety 
Officer. 
1.2.8. Vaccine 
Many countries use Bacillus Calmette-Guérin (BCG) vaccine as part of their 
TB control programmes, especially for infants. According to the WHO, this is 
the most often used vaccine worldwide, with 85% of infants in 172 countries 
immunized in 1993 (WHO 1995).This was the first vaccine for TB and 
developed at the Pasteur Institute in France between 1905 and 1921 (Bonah  
2005). The protective efficacy of BCG for preventing serious forms of TB (e.g. 
meningitis) in children is greater than 80%; its protective efficacy for 
preventing pulmonary TB in adolescents and adults is variable ranging from 0 
to 80% (Bannon and Finn 1999). 
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In South Africa, the country with the highest prevalence of TB, BCG is given 
to all children under age three (WHO 2007). However, BCG is less effective in 
areas where mycobacteria are less prevalent; therefore, BCG is not given to the 
entire population in these countries. In the USA, for example, BCG vaccine is 
not recommended except for people who meet specific criteria (CDC 
2000).Infants or children with negative skin test results who are continually 
exposed to untreated or ineffectively treated patients or will be continually 
exposed to multidrug-resistant TB. 
Healthcare workers considered on an individual basis in settings in which a 
high percentage of MDR-TB patients has been found, transmission of MDRTB 
is likely, and TB control precautions have been implemented and were not 
successful. 
BCG provides some protection against severe forms of pediatric TB, but has 
been shown to be unreliable against adult pulmonary TB, which accounts for 
most of the disease burden worldwide. Currently, there are more cases of TB 
on the planet than at any other time in history and most agree there is an urgent 
need for a newer, more effective vaccine that would prevent all forms of TB, 
including drug resistant strains in all age groups and among people with HIV 
(Jerry, 2006). 
Several new vaccines to prevent TB infection are being developed. The first 
recombinant tuberculosis vaccine rBCG30, entered clinical trials in the United 
States in 2004 (NIAID  2004). A very promising TB vaccine, MVA85A, is 
currently in phase II trials in South Africa (Ibanga et al 2006), and is based on 
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a genetically modified vaccinia virus. Many other strategies are also being used 
to develop novel vaccines (Doherty and Andersen 2005). 
1.2.9. Mycobacterial cellular envelope 
Mycobacteria produce an extremely uncommon cell wall structure; the 
peptidoglycan contains N-glycolylmuramic acid instead of the usual N-
acetylmuramic acid, found amongst most other bacteria. A far more distinctive 
feature is that up to 60% of the mycobacterial cell wall is composed of lipids 
that consist basically of uncommon long-chain fatty acids with 60 to 90 
carbons, denominated mycolic acids (Brennan and Nikaido 1995). Mycolic 
acids are branched fatty acids that have a short and a long branch, with 22 to 24 
and 40 to 64 carbons, respectively (Jarlier and Nikaido 1994); they are 
covalently linked to the polysaccharide that composes the cell wall, the 
arabinogalactan, which in turn is attached to peptidoglycan by a phosphodiester 
link (Brennan and Nikaido 1995). Approximately 10% of the arabinose 
residues in the arabinoglactan are substituted by mycolic acids (McNeil and 
Brennan 1991). The cell wall also contains several other free lipid species, 
which are not covalently attached to this basal skeleton. These lipids can act as 
antigens in the host (Brennan and Nikaido 1995). In I 982, Minnikin proposd a 
new cell wall model where the mycolic acid chains are packed side by side 
perpendicular to the cell surface, and this inner leaflet of long-chain fatty acids 
is covered by an outer leaflet composed of  extractable lipids, thereby  
reproducing an asymmetric lipid bilayer. Recently, this model was updated by 
mycobacterial cell wall X-ray diffraction studies. Another distinguishing 
property shared among mycobacteria is the fact that their cell wall retains 
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carbol fuchsin dye even in the presence of acidic alcohol, for this reason the 
rod-shaped mycobacteria are also known as acid fast bacilli (Glickman and 
Jacobs 2001). M. tuberculosis produces a considerably diverse array of 
lipophilic molecules, which range from simple fatty acids, such as palmitate 
and tuberculostearate, to long-chain complex molecules, such as mycolic acids 
and phenolphthiocerol alcohols (mycoside attachment) (Cole et al 1998). 
Although Mycobacteria have various cell wall lipid types, some are limited to 
specific species, such as sulfolipids, solely present in M. tuberculosis and 
which are involved in its pathogenicity (Brennan and Nikaido 1995). 
Furthermore, the mycobacterial cell wall fluidity gradient appears to have an 
opposite orientation to all Gram-negative bacteria, as the more external regions 
are more fluid than the internal ones (Brennan and Nikaido 1 995). 
Mycobacteria possess membrane proteins that form selective cationic channels 
called porins that control or retard the diffusion of small  hydrophilic 
molecules, thereby conferring low cell wall permeability to hydrophilic solutes 
(Jarlier and Nikaido 1994). Amongst mycobacterial species, M. tuberculosis is 
one of the more permeable to hydrophilic antimycobacterial agents, and, 
thereby, less resistant to such drugs (for instance, ethambutol) (Brennan and 
Nikaido 1995, Jarlier and Nikaido 1994). Since mycobacteria are relatively 
resistant to drying, alkali, and many other chemical disinfectants, it is thus very 
difficult to prevent M. tuberculosis transmission in urban institution 
environments. This resistance, and the resistance to therapeutic agents, are both 
basically conferred by the extremely uncommon mycobacterial cell wall 
structure (Brennan and Nikaido 1995). The unusual cell wall also permits the 
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microorganism to survive inside the macrophage, which would usually destroy 
phagocytosed pathogens (NSB Editorial Comment 2000). 
Although the cell wall acts as an exceptional permeable barrier, resistance to 
drugs in Mycobacteria  normally requires the participation of additional 
mechanisms, such as the removal of incorporated antibiotic molecules through 
chemical modification by ß -lactamases that, synergistically, confer significant 
resistance levels (Jarlier and Nikaido 1994). Thereby, since M. tuberculosis has 
a cell wall with a relatively high permeability, the inactivation of the second 
factor in synergism may allow an effective chemotherapy. M. tuberculosis cell 
wall has become a target of the more recent researches towards the elucidation 
of the mechanism of action of many old drugs and the search of targets for the 
design of new ones (Brennan and Nikaido 1995). New data on genes 
specifically involved in its synthesis may represent potential drug targets 
(Young 1998). 
1.2.10. M. tuberculosis latency anti reactivation: 
Latent TB is a clinical syndrome caused by exposure to M. tuberculosis, 
followed by establishment of infection and host’s immune response to control 
bacillary growth, forcing it into a quiescent state in the infected tissue. It is 
characterized by a reduction of bacterial metabolism, as a consequence of the 
action of cellular immune response, and which can, to a certain point, contain, 
but not eradicate, the infection. Contrary to active TB, latent TB is not an 
infectious disease and, therefore, does not represent a public health threat. 
Since latent TB is not presented as a clinical illness, the sole form to be 
diagnosed is by tuberculin skin tests. A positive result indicates that the patient 
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has already had contact with the microbe. The method relies on the intradermal 
inoculation of PPD. In certain cases, the infection can be identified through a 
chest X-ray radiography that demonstrates scars of an old infection. 
As the immune system begins to fail, latent infection can be reactivated, 
leading to the development of active TB, frequently several decades after initial 
infection. Reactivation can be induced by various factors, all of which 
compromise the immune system efficacy, such as HIV co-infection, 
malnutrition, aging, drug use, cancer, diabetes, chronic renal insufficiency and 
immunosuppressive drug therapy (Parrish et al 1998). 
1.2.11. Other causative agents of tuberculosis 
The M. tuberculosis complex includes four other TB-causing: M bovis, M. 
africanum, M. canetti and M. microti (van Soolingen et al 1997) M. africanum 
is not widespread, but in parts of Africa it is a significant cause of tuberculosis 
(Niemann et a1 2002, Niobe-Eyangoh et al 2003). M. bovis was once a 
common cause of tuberculosis, but the introduction of pasteurized milk has 
largely eliminated this as a public health problem in developed countries ( 
Thoen et al 2006, Vinay et al 2007). M. canetti is rare and seems to be limited 
to Africa, although a few cases have been seen in African immigrants (Pfyffer 
et al 1998). M. microti is mostly seen in immuned, efficient people, although  it 
is possible that the prevalence of this pathogen has been underestimated 
(Niemann et al 2000). 
Other known pathogenic Mycobacteria includes Mycobacterium Ieprae, 
Mycobacterium avium and M. kansasii. The last two are part of the non- 
tuberculosis Mycobacteria (NTM) group. Nontuberculous mycobacteria cause 
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neither TB nor leprosy, but they do cause pulmonary diseases resembling TB 
(American Thoracic Society  1997). 
1.2.11.1. Mycobacteria other than tuberculosis (MOTT) 
For many years following the discovery of the human tubercle bacillus, only 
the three acid-fast species presently known as Mycobacterium tuberculosis, M. 
bovis, and M. leprae were consistently recognized as human pathogens. As 
early as 1935, Pinner applied the term “atypical acid-fast microorganisms’ to 
some isolates that appeared to be the cause of human disease but that he could 
differentiate from M. tuberculosis on the basis of colony morphology, pigment, 
and virulence in animals (Pinner 1935). 
1.3. Human immunodeficiency virus (HIV): 
HIV is a member of the genus Lentivirus, part of the family of Retroviridae 
and is a lentivirus (a member of the retrovirus family) that causes acquired 
immunodeficiency syndrome (AIDS) (Weiss 1993, Douek et al 2009), a 
condition in humans in which the immune system begins to fail, leading to life-
threatening opportunistic infections. Infection with HIV occurs by the transfer 
of  blood, semen, vaginal fluid, pre-ejaculate, or breast milk. Within these 
bodily fluids, HIV is present as both free virus particles and virus within 
infected immune cells. The four major routes of transmission are unsafe sex, 
contaminated needles, breast milk, and transmission from an infected mother to 
her baby at birth (prenatal transmission). 
 Lentiviruses have many common morphologies and biological properties. 
Many species are infected by lentiviruses, which are characteristically 
responsible for long-duration illnesses with a long incubation period (Levy 
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1993). Lentiviruses are transmitted as single-stranded, positive-sense, 
enveloped RNA viruses. Upon entry of the target cell, the viral RNA genome is 
converted to double-stranded DNA by a virally encoded reverse transcriptase 
that is present in the virus particle. This viral DNA is then integrated into the 
cellular DNA by a virally encoded integrase, along with host cellular co-factors 
(Smith et al 2006), so that the genome can be transcribed. After the virus has 
infected the cell, two pathways are possible: 
either the virus becomes latent and the infected cell continues to function or the 
virus becomes active and replicates, and a large number of virus particles that 
can then infect other cells are liberated. 
There are two species of HIV known to exist: HIV- I and HIV-2. HIV-I is the 
virus that was initially discovered and termed both LAV and HTI                VI-
III. It is more virulent, more infective (Gilbert et al 2003), and is the cause of 
the majority of HIV infections globally. The lower infectivity of HIV-2 
compared to HIV-l implies that fewer of those exposed to HIV-2 will be 
infected per exposure. Because of its relatively poor capacity for transmission, 
HIV-2 is largely confined to West Africa (Reeves and Doms 
2002). 
1.3.1. Mycobacterium tuberculosis-HIV Co-infection 
It was estimated that the risk of developing active TB among HIV and M. 
tuberculosis co-infected people was approximately 8% per year, compared to 
10% risk, throughout life-time for people infected solely with the bacillus 
(Bloom and Murray 1992). As the immune system withers due to HIV 
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infection, the probability to develop the disease increases up to 30 times 
(Pasqualoto and Ferreira  2001). 
An increase in TB susceptibility is associated with the first HIV infection 
stages, accelerating its progression to acquired immune deficiency syndrome 
(AIDS) (Young 1998). The incidence of double infection cases occurs mainly 
among workers in high productivity age, such as 15 to 59 years old (Narain et 
al 1992). Among patients with AIDS (immune suppressed) there can be 
opportunistic infections, caused by the so called atypical mycobacteria, which 
include the M. avium complex, M. kansasii, M. fortuitum, and M. chelonae, 
although these species are essentially saprophytic (Brennan and Nikaido 1995). 
Currently, HIV infection represents the major risk for the progression of a 
latent infection into the active disease. Furthermore, TB induces AIDS 
development in IIIV-positive patients by the production of stimulatory 
cytokines and a decrease in CD4 cell charge. Therefore, HIV- M. tuberculosis 
co-infection represents a devastating problem to both, infected patients and the 
global population. In the last decades, a dramatic increase in TB incidence in 
Africa has been observed. 
A study performed in this continent demonstrated that there are several 
evidences that demonstrate the strong association between these two infections, 
as: TB is the most important disease associated to HIV and AIDS-defining 
disease; TB is the principal cause of mortality among patients HIV-infected in 
hospitals TB incidence increase coincides within period., region and population 
with the appearance of AlDS; HIV is more present among people with TB than 
within the whole population; active TB is more common among HIV positive 
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individuals than negative ones.  There are approximately 20 million people 
infected with HIV in sub-Saharan Africa, and half of these are co-infected with 
TB. According to the WHO, one third of the increase in TB incidence in the 
last 6 years was attributed to HIV co-infection. In Brazil, it is estimated that 
200,000 people are co-infected with TB and HIV. The synergism established 
between these two infections rendered them the designation of cursed due to 
HIV infection has drastically changed TB epidemiology and natural history, 
causing an increase in its transmission dynamic, morbidity and mortality. TB 
diagnosis among HIV-positive patients became more difficult to be performed 
due to various factors, such as: false negative tuberculin skin tests; pulmonary 
TB with atypical chest X-ray findings or with sputum smears negative for acid 
fast bacilli; and extra-pulmonary TB (Fätkenheuer et al 1999). It is evident that 
HIV epidemic favors the emergence of drug-resistant strains of the TB bacillus 
in co-infected patients since, in these cases; there is a higher treatment abandon 
rate (Brennan 1997). Mortality rates among HIV positive patients infected with 
MDR-TB frequently exceed 80%, and the period between the diagnosis and 
death usually ranges from 4 to 16 weeks (Riley 1993). For these reasons, 
MDR-TB is currently known as .the most malignant opportunistic infection yet 
associated with HIV infection. (Nolan 1997). 
The HIV epidemic has had a dramatic impact on TB rates and control globally. 
It is estimated that one-third of the 40 million people living with HIV/AIDS 
worldwide are co-infected with TB. Globally, TB is the most common cause of 
death among HIV-infected individuals, accounting for approximately one-third 
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of AIDS deaths annually (Corbett et al 2003). Conversely, in 2004, 15% of 
persons dying from TB were co-infected with HIV (WHO Report 2006). 
A study that examined the interaction through the Canadian AIDS surveillance 
system found that 5.6% of the cumulative AIDS cases reported in Canada 
between the years 1994 and 2003 also had TB. Of these, two- thirds were 
foreign-born and almost one-tenth were of’ Aboriginal origin (Long, and Ellis, 
2007). in another study, of TB cases diagnosed in 1 997 and 1998, 22% had a 
record of an 1IIV test, and among those whose test results were known the 
Prevalence o HIV infection was 1 5%. For the entire cohort, the prevalence of 
H1V was 3%. (Long et al 2002, Harris et al 2006). 
 Soon after the recognition of AIDS as a novel clinical entity, it became evident 
that the characteristic profound suppression of cell-mediated immunity that 
normally is the major defense against mycobacterial diseases was permitting 
disseminated mycobacterioses to occur in individuals with AIDS (Greene et al 
1982, Zakowski et al 1982). Approximately 90% of the mycobacterioses in 
AIDS patients involve either M. avium or M. tuberculosis (Peters et al 1989. 
Good 1985). 
Peters and colleagues (Peters et al 1989) have not found mycobacterial 
infection in immunosuppressed individuals who are not infected with human 
immunodeficiency virus, such as recipients of heart transplants and cancer 
patients, whose CD4/CD8 ratios were in the AIDS range, and they suggest that 
the isolation of PPEM (potentially pathogenic environmental mycobacteria) is 
highly correlated with a human immunodeficiency virus-related 
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immunosuppression. There also appears to be some level of specificity of 
susceptibility to certain strains of mycobacteria in AIDS patients. 
Hampson and colleagues reported that the DNA from strains isolated from 
A1DS patients tends to exhibit one dominant RFLP pattern, which was distinct 
from patterns seen with isolates from patients without AIDS or from stools of 
healthy control subjects (Hampson et al 1989). 
Sub-Saharan Africa bears the brunt of the 8 million annual new cases of active 
TB worldwide. Thirteen of the 15 countries with the highest incidence rates of 
TB per capita lie within this region. Moreover, TB is the leading cause of death 
among HIV-infected persons (Harries et al 2001). Alarmingly, fewer than half 
of TB cases in HIV-infected patients are diagnosed before death (Mohar et al 
1992., Lucas et al 1993, Domousa           et al 1995, Rana et al 2000).The 
factors underlying our failure to rapidly diagnose and effectively treat TB are 
multiple. Patients co-infected with HIV and Mycobacterium tuberculosis (M. 
TB) have a greatly increased risk of developing active TB and progress much 
more rapidly from infection to active disease (Corbett et al 2003). This reduces 
the time available for diagnosis and instigation of treatment. Issues surrounding 
stigmatization of persons living with HIV lead to reluctance to seek medical 
assistance, and limited health-care provision in many resource-poor countries 
undoubtedly compounds the access to treatment. However, perhaps the major 
factor hampering our ability to diagnose TB in HIV patients is lack of a 
sensitive, specific, rapid point-of-care diagnostic test. The World Health 
Organization (WHO) Directly Observed Therapy Short Course (DOTS) 
programme relies on the microscopic identification of M. TB in sputum (smear 
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positivity) to diagnose TB. However, due to alteration of the normal host 
immune response to M. TB in persons with HTV, cavitations and transfer of 
bacilli into respiratory secretions is markedly reduced. As over 60% of new 
cases of pulmonary TB in some developing countries are now co-infected with 
HIV1 (Corbett et al 2003), the WHO approach to TB diagnosis and treatment 
is failing in a large number of HIV-infected patients. Indeed, smear-negative 
TB has been linked to poor treatment outcome, including death (Harries et al 
1999, Hargreaves et al 2001). 
In addition, as is seen in children, the increased prevalence of extrapulmonary 
forms of TB in HIV-infected patients is a further challenge to the management 
of TB in resource-poor settings, where access to histopathology and advanced 
imaging tests are limited or absent. The lack of a reliable, rapid test for smear-
negative TB in adults and children not only means that we often miss the 
correct diagnosis, but also that patients are often started on antituberculous 
therapy erroneously on the basis of clinical presentation alone. As many other 
opportunistic infections found in HIV patients mimic the clinical presentation 
of TB, this leads to drugs being administered unnecessarily, risking adverse 
drug reactions, drug interactions and drug resistance( Mendelson 2007). 
The rate of MDR-TB mortality is estimated to range from 40 to 60%, which is 
similar to the mortality of patients with untreated TB (Bloom and Murray 
1992). Among some of the factors responsible for the increase in MDR/XDR-
TB incidence, there is the HIV/AIDS epidemic and the increase in TB 
incidence, especially in populations with easy access to anti-TB medication. 
The principal risk factors that contribute for MDR/XDR-TB emergence are 
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patient noncompliance with the treatment and the inappropriate administration 
of drugs by clinicians (Riley 1993). The Era of antibiotics has been constantly 
marked by cycles, which consist on the introduction of new antimicrobial 
agents and the subsequent emergence of resistance to these drugs (Swartz, 
2000).Although MDR/XDR-TB patients manifest the disease in a more 
aggressive form, there is no evidence that these patients, HIV co-infected or 
not, are more prone to transmit the infection than patients with drug-susceptible 
TB, nor that these drug-resistant strains are more infectious than drug-
susceptible ones. In HIV-negative patients, MDR/XDR-TB frequently leads to 
considerable loss of weight, respiratory insufficiency, and the formation of 
lung cavitary lesions. In contrast, in HIV-positive patients, MDRIXDR-TB is 
more aggressively developed, leading to high mortality rates (Riley 1993). A 
study performed in Florida with HIV positive patients revealed that, since 
diagnosis, the mean duration of survival is approximately 45 days for MDR-TB 
co-infected patients and 430 days for drug-susceptible TB co-infected ones 
(Fischl et al 1992). The WHO estimates that around 50 million people are 
infected with MDR-TB, which is more difficult and expensive to be treated, 
and more likely to be fatal. In industrialized nations, the complete treatment 
costs about US$ 2,000 per patient, much cheaper than the US$ 250,000 
required to treat an MDR-TB patient (Pasqualoto and Ferreira 2001). M. 
tuberculosis resistant strains are usually scarce in regions where there is little 
availability of drugs to fight the disease, since non-treated TB patients either 
die, get spontaneously cured, or become chronic bacilli disseminators, but, in 
any case, their infecting bacteria will rarely develop any kind of drug-
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resistance. In contrast, easy drug access and inappropriate chemotherapy 
conditions will always inevitably lead to drug-resistance (Petrini and Hofnner, 
1999). Therefore, MDR/XDR-TB is less common in developing nations, 
although high TB rates arc usually present, owing to the lack of medications. 
However, among developed nations, where there is a greater availability of 
anti-TB medications, the MDR/XDR-TB rates tend to be much higher (Riley 
1993). Inappropriate chemotherapy is defined as the use of a single drug, 
inappropriate combinations of drugs, short treatment periods resultant of 
patient noncompliance, and low absorption of the administered drugs. In these 
conditions, M. tuberculosis will be exposed to sub-lethal antibacterial 
concentrations, which impose a selection favorable to the growth of resistant 
bacilli among an originally susceptible population. When dealing with the 
detection or suspicion of resistance, one should avoid the addition of a single 
drug into the treatment, even though it shows an initial actively, as this 
situation resembles a monotherapy, which allows the development of resistance 
to a drug to a bacterial strain already resistant to a different agent (Petrini and 
Hoffner 1999). 
1.4. Epidemiology of tuberculosis 
Based on tuberculin skin test reactivity, epidemiologists estimate that around 
one third of the world population (1.7 billion people) is infected with M. 
tuberculosis, and at risk of developing active TB. Statistical data indicate the 
occurrence of 8 to 10 million new TB cases and 3million deaths annually, 
afflicting mostly the young and productive adults. Under the current 
conditions, it is expected in a decade that 90 million people will develop the 
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disease and 30 million will die from TB (Enarson and Murray 1996). TB 
seems, to a certain point, under control in developed countries such as Japan 
and United States, but detains a violent manifestation in other places like 
southeastern Asia, Africa, and some regions of the Pacific, mostly due to 
complications of HIV infection and drug resistance (Brennan 1997). 
Approximately 95% of TB cases occur in developing nations, where 98% of 
the world TB death cases happen. According to the WHO databank, in 1998 
Brazil occupied the 13th position among 22 countries where TB was well 
disseminated (Ruffino-Netto 2002). 
A recent report suggests that there are 20 million cases of active tuberculosis in 
the world and that around 5000 people die from tuberculosis every day (Barnes 
et al 1991). The annual incidence of the disease is expected to be increased by 
41% between 1998 to 2020 and achievement of WHO targets by 2010 would 
prevent 23% cases by 2020 (Dye  et al 1999). The global distribution of TB 
cases is skewed heavily towards low-income and emerging economies. The 
highest prevalence of cases is in Asia, where China, India, Bangladesh, 
Indonesia, and Pakistan collectively make up over 50% of the global burden. 
Africa, and more specifically sub-Saharan Africa, have the highest incidence 
rate of TB, with approximately 83 and 290 per 100,000, respectively. TB cases 
occur predominantly (approximately 6 million of the 8 million) in the 
economically most productive 15- to 49-year- old age group (Dye et al 1999). 
Our understanding of TB epidemiology and the efficacy of control activities 
have been complicated by the emergence of drug-resistant bacilli and by the 
synergism of TB with HIV co- infection ((Mendelson 2007). 
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1.4.1. Burden of TB in Sudan 
Sudan is shouldering 8-11% of the TB burden in the Eastern Mediterranean 
Region, the estimated incidence of new smear-positive cases of 90 per 100,000 
populations that gives a total of 27,805 estimated new smear-positive cases for 
a 30.894 million population in north Sudan. In addition, it has been estimated 
that the prevalence of all cases in 2008 was to be 360 cases per 100,000 
populations. The overall estimated death rate including HIV infected TB cases 
was 62 per 100,000 population. The overall case notification among 30.894 
million populations covered by the national TB programme (1999-2008) 
averaged to about 25,000 cases of all forms of TB, with 50% smear-positive 
cases (43% new smear positive and 7% re- treatment cases). In the year 1999, 
the maximum case notification reached 26,950, but since then, case notification 
showed gradually declining plateau. In the year 2008, the notification was 
21422 cases. The detection rate for smear-positive cases was 32.6%, with a 
case detection rate of all forms as 38.5%.(area covered by NTP services in 15 
northern state In addition, males constitute the greater proportion among new 
smear-positive cases in the years 2007 and 2008 (60% - 62.5%) giving a male 
to female ratio of 1.6 : 1. In the year 2008, age distribution of new smear-
positive cases shows that the majority (77.2%) of cases were between 15 and 
54 years of age. These data are in compliance with the global trends that the 
majority of cases are in their productive ages. This may reflect also the 
economical burden. Children under 14 years comprise about 5.9% of all new 
smear positive cases. It was also observed that, the ratios of males to females 
were about 1: 1 at younger ages and the gap increases in the favorite of males 
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in advanced ages to be 2: 1, only seven out of 15 states (Khartoum, Gezera, 
While Nile, Gadarif, Kassala, Red Sea, and North Kordofan) account for 
76.7% of the total case notification in North Sudan. Khartoum State 
(population of 5.4 million) alone shoulders 30.7% of total case notification in 
Sudan. The above-mentioned 7 states account for 63.9% of the total population 
of the Sudan (30.894 million). The average new smear-positive detection rate 
for these states was 45% and for all cases was 55%. Khartoum and Red Sea 
states had achieved 70% detection of new smear positive in 2004 followed by 
the White Nile in 2006. 
TB hits hard people of low socio-economic classes, marginalized population 
and IDPs. As shown by unpublished study on delay in the diagnosis in 2004, 
80% of all TB cases in the study were with family income of less than $100 per 
month and that less than 5% were with incomes of more than $200 per month. 
Moreover, 66% of the TB patients were either illiterate or with less than 6 
years of schooling (NTP 2008,). Apart from the existing poverty, TB is 
worsening the situation by affecting the economically active members of these 
families. 
Lastly, 95.9% of the new smear-positive cases had been evaluated for their 
treatment outcome in the year 1999, with a treatment success rate of 75% of all 
registered new smear- positive cases. 
On the same way, the evaluation rate jumped to 97% in the year 2008, while 
the treatment success rate was 82% of all registered new smear-positive cases. 
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An estimated annual risk of infection of 1 .8% which gives an incidence of 
90/100,000 smear positive cases that puts Sudan among the high prevalence 
countries for TB in the East Mediterranean Region(NTP  2008). 
1.5. M. tuberculosis genome  
The complete genome sequencing of the best characterized M. tuberculosis 
strain, H37Rv, allowed the identification of unique microbial features. This 
pathogen has a circular chromosome with 4,411,529 base pairs with a 65.6% 
G+C content. It is important to point out that a feature that differentiates M. 
tuberculosis from any other bacteria is the presence of a genome with 
approximately 4000 genes, mostly coding for enzymes involved in lipolysis 
(for bacterial survival inside its host) and lipogenesis (for cellular envelope 
synthesis) (Cole et al 1998).These are usually clustered, indicating the 
existence of insertion hot spots, which may prevent gene inactivation. There 
have been at least two prophages detected in its genome, which can be 
involved with the fact that M. tuberculosis has a low lysis level in culture. 
Interestingly, about 59% of the genes arc transcribed in the same direction as 
the replication cycles of the former one. Among secreted proteins that were 
identified in the mycobacterial genome sequence that could act as virulence 
factors are phospholipases C, lipases and esterases, which might attack cellular, 
or vacuolar membranes, as well as several proteases. One of these 
phospholipases is involved in bacterial persistence in the nutrient-limited 
phagosome environment. 
As the genome sequencing of M. tuberculosis H37Rv was completed, it was 
estimated that approximately 16% of its genome is dedicated to the 
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codification of unknown proteins, which might be involved in specific 
mycobacterial functions, and can be interesting as potential drug targets and as 
antigens in vaccines. Strategies based on the discovery of new targets require 
the identification of specific biochemical pathways from mycobacteria and 
related organisms. Many of these metabolic processes occur during the 
biosynthesis of mycobacterial cell wall components, and some new attractive 
targets have appeared. 
The comprehension of the synthesis of the characteristic mycobacterial cell 
wall through the use of mycolic acids synthesis inhibitors can possibly lead to 
the development of new antimycobacterial agents (Ducati et al 2006). 
1.6. Diagnosis 
The tuberculin skin test is the epidemiological surveillance method currently 
disseminated throughout the world, and can be used to detect infections from 
many years past or even very recent ones (Bloom and Murray 1992), and it is 
the only way to detect a latent infection by the Koch’s bacillus, through 
delayed type hypersensitivity against mycobacterial antigens (Glickman and 
Jacobs 2001). However, BCG vaccination also produces reactivity to PPD, 
making the use and trust worthiness of this method gradually lower as child 
BCG vaccination increases (Bloom and Murray 1992). 
Diagnosis and treatment of pediatric TB have several difficulties due to various 
factors, since young children rarely expectorate, tuberculin skin tests are not 
always easily interpreted, as false positive results can occur due to BCG 
vaccination, which is routinely given at birth; and false negative results can 
frequently occur in immune suppressed patients (Fätkenheuer et al 1999). The 
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progress of molecular techniques allowed the development of more sensitive 
and rapid methods for the detection and identification of mycobacteria. Many 
of these methods are commercially available, with sensitivity and specificity 
usually superior to 90%. However, one of the main problems here relies on the 
cost of these methods, restricting their use to developed nations. Molecular 
detection methods usually initiate with genomic sequence amplification, 
generally through polymerase chain reaction (PCR), which uses specific 
repetitive or DNA single copy sequences, and can give a specific and sensitive 
diagnosis in a few hours (Caws and Drobniewski 2001, Bloom and Murray 
1992). There are many mycobacterial genes that confer resistance to drugs 
caused by specific mutations, such as PCR single strand conformation 
polymorphism analysis, heteroduplex analysis, mutation-specific priming, 
restriction enzyme analysis, and solid-phase hybridization methods. Other 
rapid detection systems have recently been developed as an alternative based 
on phenotypic methods, which can be adapted for use in susceptibility tests. 
One of these techniques uses mycobacteriophages with the lux gene inserted in 
the genome, for example; other methods include flow cytometry and reverse 
transcriptase PCR (Caws and Drobniewski 2001). 
In order to have a better understanding of pathogenicity it becomes necessary 
to know the classes or groups of proteins and their variants. Therefore, 
proteomic use and complex disease phenotypes. The identification of all 
protein variants, their inter-relations, and the functional consequences 
generated by changes in their levels should be considered to understand the 
clinical presentation of complex diseases. (Fortina et al 2002). 
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1.6.1. Methods for the diagnosis of tuberculosis 
1.6.1.1. A-conventional approaches 
The diagnosis of tuberculosis is largely based on conventional approaches, 
which rely on clinical features and the result of microscopy and culture 
(Fukunaga et al 2002, Li et al 2000). 
1.6.1.1 .1. Microscopical diagnosis 
Acid fast and Auramine-Rhodamine staining are rapid and inexpensive 
methods for diagnosis of tuberculosis but their sensitivity is low. The number 
of bacilli in specimen stained with Acid-fast and Auramine Rhodamine 
staining seems to be much lower than that expected from the sputum smear 
data or the patient’s condition (Salian et al 1998, Fukunaga et al 2002, Sharma 
et al 2007). 
1.6.1.1.2 Culture and morphological characteristic 
Culture methods are sensitive and specific but they are slow and take 2-6 
weeks (Li et al 2000, Fukunaga et al 2002). 
Two slopes of LJ medium should be inoculated per specimen. In areas where 
M. bovis may be a problem, an additional slope containing pyruvate should be 
added. Typical colonies of M. tuberculosis are rough, crumbly, waxy, non-
pigmented (cream coloured) and slow- growers, i.e., only appearing three 
weeks after inoculation or need more time. 
1.6.2. The identification of Mycobacteria 
Early identification of Mycobacteria to the species level is important because 
of the clinical significance; some species are pathogenic while others are less 
pathogenic, (Kamerbeek et al 1997) but they can cause clinically serious 
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diseases especially in immunocompromised patients.. Knowledge of species is 
also critical in order to provide adequate patient management because; specific 
antimycobacterial drugs are required against different pathogenic 
Mycobacterium species (Gamboa et al 1998). The conventional methods for 
the identification of Mycobacterium currently are based on culture and 
biochemical tests. However, because the organism is slowly growing, 
laboratory diagnosis by these methods can take as along as eight to ten weeks 
(Springer et al 1996). 
Alternative techniques have been established, such as thin layer 
chromatography, gas-liquid chromatography, high-performance liquid 
chromatography (HPLC), and molecular techniques based on amplification, or 
sequencing of nucleic acids (Eisenach et al 1991, Cormican et al 1992, 
Kirschner et al 1993, Fodor 1995). 
Mycobacterial identification based on biochemical and/or physical 
characteristics is a labour-intensive, slow, often limited process. (Turenne et a1 
2001, Wayne 2004). 
Methods based on molecular gene target sequencing, such as 16S rRNA, 
provide rapid, concise, tangible data and can be used in the absence of 
organism propagation. Rapid, accurate species identification is a necessity for 
both epidemiologic studies and determination of general antimicrobial 
susceptibility patterns. For these reasons, mycobacteriology laboratories 
performing susceptibility testing should differentiate M. tuberculosis from M. 
bovis and M. bovis BCG because of the intrinsic resistance of the latter two 
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organisms to pyrazinamide and the impact on epidemiologic tracing (Niemann 
et al 2000). 
1.7. Drug sensitivity testing  
There are three widely used methods for drug sensitivity testing on 
Lowenstein-Jensen medium: (1) The absolute concentration method (also 
referred to as minimal inhibitory concentration [MIC] method); (2) the 
resistance ratio method; and (3) the proportion method (Canetti et al 1963). 
There are other methods as well: agar-based semi-synthetic media and vertical 
diffusion methods. 
1.7.1. Proportion method 
Strains identified as belonging to the M. tubercu1osis complex are routinely 
tested for their susceptibility to isoniazid, rifampcin, streptomycin, and 
ethambutol. The IUTM Lowenstein-Jensen medium is used with and without 
incorporation of drugs at the recommended concentrations. 
1.7.2. Molecular methods 
The rapid development and availability of a variety of new molecular genetic 
technologies present in the clinic are array of options for the accurate diagnosis 
of infectious diseases. This is particular in case of tuberculosis. Molecular 
techniques used as a diagnostic tool in tuberculosis, though it is rapid and 
sensitive but yet their clinical validity remains controversial and consequently, 
the application of gene amplification to routine diagnosis of tuberculosis is 
important and need to be studied. The increasing incidence of MDRTB world 
wide has placed emphasis on the need for early detection of drug resistance and 
therefore, also the need for earnest search for new drugs (Fukunaga et al 2002). 
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Molecular methods for the diagnosis of tuberculosis have improved in recent 
years and several molecular techniques for its diagnosis have been introduced 
for clinical use. Molecular methods provide several advantages, including 
confirmation of the presence of Mycobacterium tuberculosis within 1 to 3 day 
(Fukunaga et al 2002). 
1.7.2 .1. Nucleic acid amplification testing 
Positive smears can be tested by an amplification test. Nucleic acid 
amplification (NAA) tests, which amplify target sequences of DNA or RNA 
from the M. tuberculosis organisms, are complex and expensive tests but have 
several important advantages (Catanzaro et al 1997, Heifets 2003). They are 
rapid, have excellent specificity and provide results within 3 to 24 hours. 
Additionally, they are more sensitive than AFB smears, although less sensitive 
than TB cultures (Catanzaro et al 1997). 
1.7.2.1.1. Simplified multiplex PCR assay 
Because the incidence of non tuberculosis mycobacteria (NTM) infection is 
increasing, any methods capable of simultaneously determining the presence of 
M. tuberculosis and/or NTM would be useful. For this purpose, multiplex PCR, 
which simultaneously uses two or three different genes, has been frequently 
used, as the technique which can specifically detect and identify different 
species of the genus Mycobacterium (Del Portillo et al 1996, Klemen et al 
1998, Mustafa et al 1999) and differentiate members of the M. tuberculosis 
complex (Del Portillo et al 1996) in the routine diagnostic laboratory by using 
Mycobacterium genus- and species-specific genes. However, some of these 
genes have been found to lack specificity for M. tuberculosis. In addition, 
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1S6110 PCR has been reported to produce false- negative (Yuen et al 1993) 
and false-positive (Kent et a1 1995) results, and the mtp40 gene is not present 
in all M. tuberculosis strains (Weil et al 1996). In a study by Kim et al (2003), 
they used a simplified multiplex PCR assay, basically a duplex PCR (DPCR) 
assay, to differentiate M. tuberculosis complex and NTM by using a single 
gene, the RNA polymerase-subunit encoding gene (rpoB). 
1.7.2.1.2. Single tube multiplex-PCR 
It is a rapid differentiation of Mycobacterium bovis and Mycobacteriurn 
tuberculosis based on a 12.7-kb fragment by a single tube multiplex-PCR. 
Recently, sequence analysis of the M. tuberculosis and M. bovis genomes has 
shown that M. bovis lacks a 12.7-kb fragment present in the genome of 
M. tuberculosis (Zumarraga et al 1999). Further analysis of the 12.7-kb 
fragment suggested that it represents a deletion in M. bovis rather than an 
insertion in M. tuberculosis. This deletion removes most of the mce-3 operon, 
one of the four closely related operons, which may be involved in cell entry. 
Therefore, it was suspected that this deletion might contribute to differences in 
virulence or host range in the two species. Interestingly, all the M. tuberculosis 
isolates studied showed the presence of the 12.7-kb fragment, while all the M. 
bovis strains lacked this fragment (Zumarraga et al 1999). Therefore, the 12.7-
kb fragment may be a useful marker to differentiate M. bovis from M. 
tuberculosis in a single tube multiplex-PCR (m-PCR) assay. 
A common forward primer, CSB1, was designed to hybridize the 229-bp 
sequence found in both M. bovis and M. tuberculosis, and complemented bases 
50 -66. 
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The M. bovis-specific reverse primer, CSB2, complements bases 217-202 of 
the 229-bp sequence and is also expected to hybridize to the 229-hp sequence 
from both organisms, but should generate a unique 168-bp PCR product in the 
case of M. bovis only and not in M. tuberculosis. This is expected since the 
229-bp sequence, present in M. tuberculosis, is interrupted at position 197 by a 
unique 12.7-kb fragment. In principle, in a PCR reaction, the 12.7-kb size 
insertion in M. tuberculosis is beyond the amplification limits of Taq DNA 
polymerase and, hence, cannot be amplified using primer CSB2. In contrast, 
M. tuberculosis specific reverse primer CSB3, which complements bases 
23,729-23,708 of the 12.7-kb fragment, is designed to hybridize to the 1 2.7-kb 
fragment and is expected to generate a unique 262-bp PCR product specific to 
M. tuberculosis. 
1.7.2.1.3- Multiplex allele-specific PCR (MAS-PCR) 
It have been developed a MAS-PCR targeting codon 315 of the katG gene, 
codons 516, 526, and 531 of the rpoB gene, the mabA-inhA promoter region 
(15), and codon 306 of the embB gene. These codons were most frequently 
involved in point mutations associated with the drug resistances under 
investigation in previous and present studies (Ramaswamy and Musser  1998; 
Slayden and Barry  2000, Zhang and Telenti  2000). The 3V end of each allele-
specific primer was positioned to pair with the base of the respective codons 
where most point mutations have been found according to the wild-type 
sequences of strain H37Rv. Thus, when no mutation exists at a targeted codon, 
the wild-type allele-specific fragment will be amplified and no allele-specific 
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PCR product will be generated when there is a mutation at the targeted codons 
or the codons nested in the primers. 
1.7.3. Genotyping of M. tuberculosis: Current Methods 
The mid-1980s saw the first integration of molecular methods to discriminate 
between clinical isolates of M. tuberculosis. While previous methods, such as 
colony morphology, comparative growth rates, susceptibility to select 
antibiotics, and phage typing, were useful, they did not provide sufficient 
discrimination, thus limiting their utility in TB epidemiology. However, given 
the plethora of molecular tools available for instance, 1S6110 RFLP, 
Spoligotyping, MIRU-VNTR (12 loci, MIRU-VNTR (15 loci) (Mathema et al 
2006). 
1.7.3.1. 1S6110 RFLP 
Gold standard for the molecular epidemiology of MTC strains, First 
standardized method, 1S6110 fingerprinting remains the single, most 
discriminatory technique for the analysis of isolates having >6 1S6110 bands. 
For instance, Lillebaek et al used 1S6110 genotyping to demonstrate 
endogenous reactivation of TB after over 30 years of latency (Lillebaek            
et al, 2002). 
The current gold standard for DNA fingerprinting is restriction fragment length 
polymorphism (RFLP) analysis based on the 1S6110 transposable element 
(Middlebrook and Cohn 1953). RFLP has high discriminatory power and 
extensive application in historical databases. There are, however, technical 
limitations to the method due to the nature of the test (McNabb et al 2002, 
Braden et al 2002). 
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1.7.3.2. Spoligotyping 
Simplest technique for MTC strain genotyping  standardized analysis for 43 
spacers. Can be performed directly on cell lysate; no DNA purification 
required. Can be performed on nonviable bacteria, less discriminatory than 
1S6110 RFLP analysis and MIRU-VNTR (12 and 15 loci) cannot recognize 
mixed infections less informative in regions with predominant or endemic 
strains; e.g., W-Beijing in China, Southeast Asia, and Russia (Mathema et al 
2006). 
1.7.3.3. MIRU-VNTR (12 loci) 
Rapid, high-throughput technique for MTC strain genotyping. Better resolution 
than spoligotyping. Digitized results (number of copies of each repeat) are very 
portable well suited for large-scale genotyping. Can be performed directly on 
cell lysate; no DNA purification required Manual analysis possible by 12 
individual PCR amplifications followed by gel electrophoresis, less 
discriminatory than IS110 RFLP genotyping. 
1.7.3 .4. MIRU-VNTR (15 loci) 
As for 12-locus MIRU-VNTR typing but with increased resolution 
(comparable to I1 6l10 RFLP) (Mathema et al 2006). 
1.8. Chemotherapy of tuberculosis 
Over the two centuries preceding this watershed, TB had taken roughly one 
billion human lives (Iseman  2000).TB chemotherapy has three identifiable 
goals: to kill rapidly the massive numbers of’ bacilli that are multiplying in 
tissues of the typically diseased hosts to prevent the emergence of clinically 
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significant strains of the drug-resistant mutants and to sterilize effectively the 
site of disease. 
The researches have emphasized the importance of combination of 
chemotherapy (Bobrowitz and Robins 1967, Snider et al 1984). The use of 
combination agents of medical therapy, should be continue and uninterrupted 
for an adequate length of time to eradicate the infection (American Thoracic 
Society 1986). 
The major concepts involved in TB therapy in individuals with non-drug 
resistant infection are: (1) all regimen should contain isoniazid (INH) due to 
effectiveness, low cost and tolerance; (2) treatment for less than 6 month leads 
to unacceptably high relapse rates; (3) pyrazinamide (PZA)should be used with 
isoniazid and rifampcin (RIF) for the first 2 month of the treatment; (4) 
intermitted therapy is as effective as daily therapy if adequately supervised 
(Fox and Mitchison  1975, Snider et al  1984). 
Non-completion of TB treatment plays a key role in the prevalence and 
resistance patterns of this infection. Supervised or directly observed therapy 
(DOT), in which medication is taken at a facility under observation of a care. 
Provider brings the medications and observes that they are taken, is the most 
effective method for improving adherence to threatening (McDoland et al 
l982). Regimens of 6 months duration comprising an initial 2-months intensive 
phase of INH, RIF, PZA with or without streptomycin (SM), followed by INH 
and RIF can be expected to yield long term success rates of 95% or greater for 
patients with drug-susceptible pulmonary disease (Iseman, 2000). 
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1.9. Drug resistance tuberculosis 
Understanding the molecular basis of resistance might lead to development of 
novel rapid method for diagnosing drug resistance. Then using them as 
diagnostic tools for tuberculosis, to prevent nosocomial and community 
epidemic spreading of MDR diagnosed and undiagnosed tuberculosis cases. To 
measure the efficiency (in vitro) of new anti- tuberculosis drugs (rifabutin, 
ofloxacin), especially in multidrug resistance strains. Detection of 
antimicrobial resistant strains will enable clinicians to make rational decisions 
about optimal antimicrobial therapy for their patients. 
The specific drug to which resistance has developed is extremely important. 
Resistance to isoniazid or rifampcin is far more serious situation than 
resistance to only streptomycin or even isoniazid plus one of the second-line 
drugs. Because isoniazid and rifampcin are the two most potent anti-
tuberculosis drugs available at this time (Kochi et al 1993, Iseman, and Madsen 
1989).They are currently used in the vast majority of treatment regimens for 
tuberculosis. Accounting for over 99% of the bacillary killing within two 
months of initiation of treatment (Koehi et al 1993; Iseman, and Madsen 1989). 
In the mid-1940s, when streptomycin was first introduced as chemotherapy for 
cavitary pulmonary tuberculosis, it was administered alone, with the result that, 
in three months’ time, 80% of patients were harbouring streptomycin-resistant 
organisms (Medical Research Council Investigation, l948). Soon it was 
understood that there was no hope curing cavitary tuberculosis with any single 
antimicrobial drug because it was impossible to prevent the selection of drug-
resistant mutants under these circumstances. Suppression of resistant mutants 
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become possible when para-aminosalicylic acid (PAS) (Lehmann, 1946) and 
isoniazid (INH) (Bernstein et al 1952) became available in 1946 and 1952, 
respectively (Medical Research Council Investigation 1950, Medical Research 
Council 1962). In the early 1950s, the rule was to treat patients with a 
combination of available drugs. Because each drug was active against the 
mutants resistant to other drugs, the selection of the drug-resistant mutants was 
prevented in the majority of cases (Medical Research Council  1962). 
A radical change occurred when rifampcin (RMP) became available 
(Grumbach and Rist 1967). 
Drug resistance tuberculosis threatens the National Tuberculosis Control 
Programmes in several countries; the major problem is multidrug resistance TB 
(MDR-TB) (WHO/IUATLD 2000). MDR-TB is defined as M. tuberculosis 
strains that are resistant to at least isoniazid and rifampcin, the two key first 
line drugs in short course TB chemotherapy. Resistance to any single TB drug 
is close to 10% in all African countries surveyed (Aziz et al 2006). 
Recently, extensively drug-resistant (XDR) M. tuberculosis (defined as 
resistant to at least isoniazid, rifampcin, and fluoroquinolone, and either 
aminoglycosides [amikacin, kanamycin or capreomycm or both] is emerging  
(WHO, 2006). 
1.9.1. Molecular drug resistance tuberculosis 
Drug resistance in M. tuberculosis is caused by mutations in relatively 
restricted regions of the genome (Musser 1995, Zhang and Te1enti 2000). 
Mutations associated with drug resistance occur in rpoB for RIF, katG and the 
promoter region of the mabA (fabGl)-inhA operon for INH, embB for 
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ethambutol (EMB), pncA for pyrazinamide (PZA), rpsL and rrs for 
streptomycin (STR), and gyrA for fluoroquinolones (FQs) such as ofloxacin 
(OFX) and levofloxacin (LVX) (Musser 1995, Zhang and Telenti 2000). For 
example, 96% to 100% of RIF resistant M. tuberculosis isolates have at least 1 
mutation in rpoB, which encodes the RNA polymerase -subunit (Zhang and 
Telenti 2000; Musser 1995; Telenti et al, 1993). Of INH- resistant isolates, 
42% to 58% have at least 1 mutation in katG, which encodes catalase-
peroxidase, and 21% to 34% carry at least 1 mutation in the promoter of mabA, 
a synonym for fabGl (Lavender et al 2005), which encodes a 3-ketoacyl 
reductase (Zhang and Telenti. 2000, Banerjee et al 1998, Musser 1995 and 
Zhang et al 1992). Of  EMB-resistant isolates, 47% to 65% have at least one 
mutation in embB, which encodes arabinosyltransferase (Zhang and Telenti 
2000, Telenti et al 1997, Musser 1995). Seventy-two to 97% of PZA-resistant 
isolates have at least one mutation in pncA, which encodes pyrazinamidase 
(Zhang and Telenti 2000, Scorpio  and  Zhang 1996 , Musser 1995). Of STR-
resistant isolates, 52% to 59% and 8% to 21% have mutations in rpsL, which 
encodes ribosomal protein S12, and rrs, which encodes 16S rRNA, 
respectively (Zhang and Telenti 2000, Musser 1995, Nair et al 1993). Of  FQ-
resistant isolates, 75% to 94% have mutations in gyrA, which encodes the A 
subunit of DNA gyrase (Zhang and Telenti  2000, Musser 1995  Takiff  et al 
1994). 
The mechanism of resistance to RMP involves missense mutations in a well- 
characterized region of the rpoB gene (encoding the b subunit of the RNA 
polymerase) (Telenti et al 1993); thus, investigation of rifampcin resistance is 
Please purchase PDFcamp Printer on http://www.verypdf.com/ to remove this watermark.
 58
relatively straight forward. In contrast, resistance to INH is associated with a 
variety of mutations affecting one or more genes such as those encoding 
catalase-peroxidase (katG) (Zhang et al 1992), the enoylacyl carrier protein 
reductase involved in mycolic acid biosynthesis (inhA) (Banerjee et al 1994), 
and the recently described alkyl-hydroperoxide reductase (ahpC), which is 
involved in the cellular response to oxidative stress (Sherman et al 1995, 
Deretic et al 1995). Therefore, cost- and time- efficient investigation of INH 
resistance will require a strategy for targeted mutation analysis. 
1.9.1.1. Rifampcin 
Rifampcin is a first line TB medication .It interacts specifically with the ß  
subunit of the RNA polymerase enzyme from prokaryotic organisms to inhibit 
transcription, leading to bacterial death (Telenti et al 1993). RMP’ was 
effective not only against actively multiplying organisms but also against the 
resting or persisting organisms responsible for relapses after treatment was 
stopped. RMP, in combination with INH and SM, effected the cure of almost 
100% of patients in a treatment period of nine months, i.e., half the time 
required with the three-drug combination of INH+SM+PAS (BTTA. 1976). 
Analysis of approximately 500 strains from global sources has found that 96% 
of Rifampcin resistant clinical isolates of Mycobacterium tuberculosis have 
mutations in the 81-bp core region of rpoB gene, which encodes the ß  subunit 
of RNA polymerase (Valim 2000; Musser 1995). These mutations are absent in 
susceptible organisms. Although minor discrepancies have been reported, in 
general there has been a strong correlation of a specific amino acid 
substitutions and MIC. Missense mutations in codons 513, 526, or 531 result in 
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high level rifampcin resistance, whereas amino acid changes at position 514 or 
533 usually result in low levels of rifampcin resistance. Molecular detection of 
resistance is relatively easy to be analyzed, since about 96% of the rifampcin-
resistance cases involve specific mutation in the rpoB gene, which codes for 
the enzymes beta chain, producing resistance to the drug through the decrease 
in binding affinity of rifampcin to the polymerase (Telenti et al 1993). The 
molecular mechanism of resistance in 4% of rifampcin resistant tuberculosis 
isolates that lack RRDR changes is unknown (Ramaswamy and Musser 1998). 
It is estimated that 90% of rifampcin-resistant isolates in some areas are also 
resistant to isoniazid, making rifampcin resistance a useful surrogate marker 
for multidrug resistance and indicating that second and third line drugs to 
which these isolates are susceptible are urgently required (Yuen et al 1999,  
Watterson et al 1998). 
1.9.1.2. Isoniazid 
The first biochemical effect of isoniazid occurs in the first stages of mycolic 
acid synthesis. Isoniazid is a synthetic pro-drug that requires the product of the 
katG structural gene for its activation (Telenti and Iseman 2000); this drug 
becomes an active compound once it is metabolized by the M. tuberculosis 
catalase-peroxidase enzyme, and inhibits the activity of the enoyl-ACP (CoA) 
reductase enzyme (encoded by the inhA gene) in the presence of NADH or 
NAD+ (Schroeder et al 2002, Basso and Santos 2005, Telenti et al 1993). 
Investigators on several continents have reported that many (50-60%) INH 
resistant patient isolates have mutations, small deletions or insertions that are 
not represented among INH sensitive control strains (Musser 1995). Mutations 
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leading to INH resistance have been identified in different gene targets 
including KatG, inha, ahpc and other genes that remain to be established 
(Ramaswamy and Musser 1998). Telenti et al (1997) analyzed Mycobacterium 
tuberculosis isolates by PCR and found that the mutation frequencies were as 
follows for INH resistant strains KatG (36.8%), inhA (31.6%), Ka1G-inhA 
(2.6%), ahpC (13.2%) and KatG-ahpC (2.6%). Amino acid replacements in the 
NADH binding site of InhA apparently result in INU resistance by preventing 
the inhibition of mycolic acid biosynthesis. Mutations in the KatG or inhA do 
not account for all INH resistant strains since 15-25% INH resistant clinical 
isolates have both wild-type KatG and inhA genes. The mutation rate 
responsible for isoniazid resistance is 100 times greater than the one 
responsible for rifampicin resistance, and is usually the first modification in the 
susceptibility of wild-type M. tuberculosis (Petrini and Hoffner 1999). Since, 
in the United Kingdom, 90% of the rifampcin-resistant isolates are also 
isoniazid resistant, a single positive resistance result to the former can be 
considered a strong indicator of MDR-TB (Caws and Drobniewski, 2001). The 
mechanism of INH resistance in some strains remains to be determined 
(Banerjee et al  1994). 
1.9.1.3. Streptomycin 
Is another first line TB drug. It acts as an inhibitor of prokaryotic protein 
synthesis initiation (Telenti and Iseman  2000). Mutations associated with 
streptomycin resistance in tuberculosis have been identified in the 16S rRNA 
gene (rrs) and rpsL gene which encodes the ribosomal protein Sl2 (Telenti and 
Iseman 2000). 
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In contrast to other bacteria that have multiple copies of rRNA genes, 
Mycobacterium tuberculosis complex members have only one copy. Therefore, 
single nucleoside changes can potentially produce antibiotic resistance. 
Mutations in the rrs are clustered in two regions around nucleotides 530 and 
951. The 530 loop 16S rRNA is highly conserved and is located adjacent to the 
915 region in secondary structure models. The majority of mutations producing 
streptomycin resistance occur in rpsL. The most common mutation is at the 
codon 43. Mutations also have occurred in codon 88. About 65-75% of 
streptomycin resistant isolates have resistance associated changes in rpsL or 
rrs. Failure to identify resistance-associated variations in these genes in 25-
35% of organisms indicates that other molecular mechanisms of streptomycin 
resistance exist (Douglas and Steyn  1993). 
1.9.1.4. Ethamutol 
EMB has been used as a primary drug for the treatment of tuberculosis since 
the 1960s (Heifets et al 1986, Iwainsky l988). Several hypotheses have been 
advanced to explain the mechanism of action of EMB. Most early studies 
pointed toward a detrimental alteration of the mycobacterial cell wall structure, 
although pleiotropic effects have been described (Beggs, et al 1973, Cheema et 
al 1985, Deng et al 1995;,Forbes et al 1965, Kilburn et al 1981, Paulin et al 
1985, Takayama , Kilburn 1989). 
Biochemical evidence has implicated arabinosyltransferases as EMB targets, 
and this concept has been supported by recent molecular genetic data obtained 
from study of M. avium, M. smegmatis, and M. tuberculosis (Belanger et al 
1996, Maddry et al 1996, Wolucka et al 1994). Telenti            et al, (Telenti et 
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al 1997) reported that mutations in the M. tuberculosis and M. smegmatis 
embCAB operon were associated with EMB resistance. 
Three contiguous genes encoding arabinosyltransferases and designated emhC, 
embA, and embB have been identified in Mycobacterium tuberculosis (Telenti 
et al 1997). The proteins encoded by these genes are about 65% identical to 
each other. Previous studies based on limited sequencing of the 10-kb region 
containing the embCAB genes have identified mutations that result in 
replacement of amino acid residues and are found only in EMB-resistant 
organisms cultured from humans. The most commonly affected amino acid 
was Met306 of EmbB (Alcaide et al 1997). Gene transfer experiments showed 
that mutations in embB conferred EMB resistance in M. smegmatis (Alcaide et 
al 1997; Telenti et al 1997). Telenti et al 1997, postulated that EmbB amino 
acid 306 is located in a cytoplasmic loop that forms an EMB resistance-
determining, region (ERDR), and Alcaide et al (1997) showed that amino acids 
in this region are well conserved among EmbB proteins made by M. 
tuberculosis, Mycobacterium leprae, M. smegmatis, and many other 
mycobacterial species. In addition, it was reported that high-level natural 
resistance to EMB was associated with a variant amino acid motif in the 
ERDRs of M. leprae, Mycobacteriurn abscessus, and Mycobacierium chelonae 
(Alcaide et al 1997). Potentially at variance with the compensatory change 
hypothesis is the report  by Telenti et al 1997, that no transcription initiation 
site was identified in the wild-type embC-embA intergenic region by primer 
extension analysis. However, it is possible that the mutations that were 
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identified create a new transcriptional start site in the mutant organisms where 
none existed previously in the wild- type strains(Ramaswamy et al 2000) 
1.9.1.5. Pyrazinamide 
It is a drug that functions only against M. tuberculosis, and no other 
mycobacterial species. Pyrazinamide resistance appears to be conferred by 
mutations in the pncA gene, which encodes pyrazinamidase, an enzyme that 
hydrolyses the drug to turn it active (Telenti and Iseman 2000).  Current 
experimental evidence indicates that pyrazinamide enters M. tuberculosis by 
passive diffusion, is converted to pyrazinoic acid by 
pyrazinamidase/nicotinamidase enzyme activity, and is excreted by a weak 
efflux pump (Zhang and Mitchison 2003). Protonated pyrazinoic acid is then 
reabsorbed into the bacilli under acidic conditions and accumulates due to the 
inefficiency of the efflux pump, leading to cellular damage. Pyrazinoic acid 
and pyrazinamide could de-energize the membrane by collapsing the 
membrane potential and affect the membrane transport function at acidic pH. 
Unlike other antilubercular agents, PZA has no defined target of action (Telenti 
and Iseman  2000). 
1.9.1.6. Fluoroquinolones 
The mode of action of fluoroquinolones is on enzymes responsible for DNA 
topological conformation, topoisomerases, mainly DNA gyrases. Resistance to 
ciprofloxacine, one of the most active fluoroquinolones against M. 
tuberculosis, is conferred by mutations to gyrA, gyrB and IfrA genes, which 
encode the subunits A and B of DNA gyrase, and an efflux protein, 
respectively. Like most wild-type M. tuberculosis strains, many of the multi-
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resistant strains are susceptible to fluoroquinolones, since these bactericidal 
compounds increase the activity of isoniazid and rifampicin (Telenti and 
Iseman 2000). 
1.9.1.7. Cycloserine 
Some second line drugs, such as cycloserine, should he used in the lack of 
alternatives, as these present greater toxicity and, thereby, can cause dangerous 
psychic collateral effects (Petrin and Hoffner 1999). 
1.10. Treatment anti chemotherapy 
The principal objective of chemotherapy in TB patients is the eradication of the 
whole bacillary load (Petrini and Hoffner  1999). Modern therapy relies on a 
combination of potent bactericidal agents, such as isoniazid, rifampicin and 
pyrazinamide, in a treatment with six month duration. Whenever there is 
resistance to at least rifampicin and isoniazid, which characterizes MDRTB 
(Telenti and Iseman 2000) it becomes necessary to extend the treatment period, 
and frequently rely on the use of second- or even third-line drugs, even though 
the increased toxicity stands as a negative factor. 
Very recently the Center for Diseases Control, CDC-USA, defined a new class 
of MDR, which was named extensively drug resistant (XDR) TB, whose 
isolates were resistant to isoniazid and rifampicin and at least three of the six 
main classes of second line drugs (aminoglycosides, polypetides, 
fluoroquinolones, thioamides, cycloserine and para-aminosalicylic acid) (CDC 
2006). In extreme cases, when an infection involves MDR or XDR strains (or 
when there is a portion of an organ considerably damaged), it becomes 
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sometimes necessary to resort to surgical removal of granulornas, as an attempt 
to increase the likelihood of cure (Telenti and Iseman 2000). 
First-line drugs are mainly bactericidal, and combine a high degree of efficacy 
with a relative toxicity to the patient during treatment; these include isoniazid, 
rifampicin, streptomycin, ethambutol, pyrazinamide, and fluoroquinolones. 
Second-line drugs are mainly bacteriostatic, which have a lower efficacy and 
are usually more toxic; these include para-aminosalicylic acid, ethionamide, 
and cycloserine, among others (Goodman et al 1996). Among all first-line anti-
TB agents, isoniazid has the greatest bactericidal activity against 
microorganisms growing actively in cavities, followed by rifampicin, 
streptomycin and quinolones. However, isoniazid can frequently cause fever, 
and is one of the drugs with the highest degree of toxicity (Morehead  2000). 
Although TB is a serious illness, it can still be cured in most new cases as long 
as, once diagnosed, appropriate chemotherapy is employed, since one of the 
greatest risks of mortality in TB is the delayed treatment. The treatment 
currently recommended by the WHO consists of the combined administration 
of isoniazid, rifampicin, pyrazinamide and strepomycin (or ethambutol) during 
the first 2 months, followed by the combination of isoniazid and rifampicin for 
at least 4 additional months chemotherapy. The patient non-compliance led the 
WHO to invest in universal treatment adherence programs, through a process 
currently known as the directly observed treatment short-course (DOTS), 
where health care workers counsel patients, perform progress surveillance, and 
make sure that each medication dose is correctly taken (NSB Editorial 
Comment 2000). 
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DOTS combines five fundamental elements: political commitment, 
microscopic services, drug supplies, surveillance systems and direct treatment 
observation. This strategy prevents the occurrence of new infections and, more 
importantly, makes MDR/ XDR-TB generation impractible (Pasqualoto and 
Ferreira, 2001). Patients with latent TB can also be treated on a chemotherapic 
basis; this treatment is based solely on isoniazid (monotherapy) and works only 
for patients with the latent infections that have not developed the active disease 
yet. (Daniel 1997). HIV-positive patients treated according to the WHO 
recommendations (DOTS) have sputum conversion and cure rates similar to 
HIV-negative treated patients. According to the WHO, there are no treatments 
currently available that have yielded definitive cure results for active TB 
patients and MDR/XDR-TB control better than DOTS (Fatkenheuer et al 
1999). Even though the efficacy of the treatment for HIV-positive and negative 
patients is quite similar when dealing with drug-susceptible M. tuberculosis 
infection, the choice for an appropriate TB treatment when drug resistance is 
suspicious can frequently be affected by the lack of rapid diagnosis tests. Drug-
susceptibility tests require approximately 8 weeks to be concluded, a period 
usually greater than co-infected patient’s survival mean time (Riley 
1993). 
There are several new developments which may have long-term effect on 
improving the therapy of  NTM infections. Moxifloxacin, telithromycin and 
quinupristin and dalfopristin have been reported to be more effective against 
M. marinum than other macrolides and antibiotics (Braback et al 2002). It has 
also been reported that mycothiol deficient mutants of                  M. smegrnatis 
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are inhibited better by antibiotics (Rawat et al 2002). Several studies have 
illustrated that mutations which seen in drug resistance isolates of M. 
tuberculosis are not frequently found in drug resistant NTM (Guerrero et al 
1994, Meier et al 1994, Portillo Gomez et al 1995, Musser 1995 Katoch 1997). 
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CHAPTER TWO 
MATERIALS AND METHODS 
2.1. Study area 
The specimens of the present study were collected from the tuberculosis 
management units (TBMUs) that distributed in the different localities of 
Khartoum state by authorities of the National Tuberculosis Programme(NTP). 
2.2. Study subjects 
Sputum of the smear positive patients and Blood specimens  
2.2.1. Inclusion criteria 
New cases patients with sputum smear positive of acid fast bacilli that were 
resident in Khartoum State.  
2.2.2. Exclusion criteria  
Smear Negative patients, and retreatment cases. 
2.3. Study design 
Descriptive cross-sectional study. 
2.4. Sample size 
252 patients were enrolled in the current study were calculated  according to 
the equation. n= (1.96)2*Pq/d2 
n= sample size, p=prevalence of the disease, q=P-1 and d=0.022 
2.5. Sampling procedure 
All samples (sputa and blood) in TBMUs /day were collected from patients 
resident in Khartoum state who agreed to participate in current study. The 
specimens were collected from the patients after being asked to give a written 
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permission to be tested for HIV. Sputum was obtained in sterile screw-caped 
plastic disposable container, without contamination with saliva or nasal 
secretions. 
2.6. Demographic and clinical data 
Structured questionnaire was formulated to include the following variables: 
residence, sex, age, tribe, income level, social status, education level, 
classification of TB, treatment regimen, past history of anti-TB therapy, HIV 
status and the previous laboratory examination of sputum. 
2.7. Laboratory investigation 
 Sputum samples from all patients and venous blood were collected. Sputum 
microscopy was done using Ziehl Neelsen (ZN) stain for acid fast bacilli 
(AFB) . Sputum samples showing smear positive for AFB were cultured for 
isolation and identification of mycobacteria. The blood samples were examined 
for presence of anti-HIV antibody using ELISA techniques. 
All procedures were carried under biological safety cabinet class II and 
chemical agents were prepared according to Kent and Kubica (1985). 
- Direct and indirect microscopical examination (decontamination and 
centrifugation mainly used for culture and to detect the low amount of 
microbes) were done. Culture of sputum specimens was carried to isolate, and 
identify MTB and atypical mycobacteria (Kent and Kubica1985). 
 
 
 
 
Please purchase PDFcamp Printer on http://www.verypdf.com/ to remove this watermark.
 70
2.7.1. Microscopical examination 
2.7.1.1. Direct Ziehl-Neelsen Stain  
Direct smear was made, fixed by heat, stained by ZN method and examined 
microscopically for the presence of acid fast bacilli as follows: Smears were 
flooded with filtered 1% carbol-fuchsin stain, heated to steaming without being 
boiled, left to stand  for 5 minutes, rinsed with tap water. Then flooded with 
25% of sulfuric acid (H2SO4) and allowed for complete destaining, then 
washed with tap water and drained. Flooded with methylene blue as 
counterstain for 1 minute, washed with water and air dried, examined under oil 
immersion objective lens (Appendix 1).  
2.7.2.Isolation of M. tuberculosis 
2.7.2.1 Decontamination and inoculation of Specimen  
Sputa were transferred to 50ml disposable plastic tubes and an equal amount of 
4% of sodium hydroxide was added, vortexed and allowed to stand at room 
temperature for 20 minutes. The specimen was neutralized with 1N HCl 
containing 0.1% phenol red as an indicator (Appendix III). 
For isolation of mycobacteria, two slopes of Lowenstein-Jansen medium (LJ) 
containing glycerol and one LJ supplemented with pyruvate medium were 
inoculated (2-4 drops or 2-4 loops-full).Then all cultures were incubated at 
35°-37°C until growth appeared or discarded and record as negative after eight 
weeks. 
The inoculated media were incubated in a slanted position for at least 24 hours 
to ensure even distribution of the inoculums. Thereafter, all bottles were placed 
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in upright position. Tops were tightened to minimize evaporation and drying of 
media (Kent and Kubica ,1985, and De Kantor, et al 1998). 
2.7.2.2 Examination schedule: 
All cultures tubes were loosen then examined 72 hours after inoculation to 
check for complete evaporation of the liquid, after that the caps were tightened 
in order to prevent drying out of the media and to detect for contaminants. 
Thereafter, cultures were examined weekly. 
• After one week to detect rapidly growing mycobacteria . 
• After three to four weeks to detect positive cultures of M. tuberculosis as well 
as other slow-growing mycobacteria which may be either harmless saprophytes 
or potential pathogens. 
• After eight weeks to detect very slow-growing mycobacteria, including M. 
tuberculosis, before judging the culture as negative. 
2.7.2.3.Reading of cultures 
Typical colonies of M. tuberculosis were rough, crumbly, waxy, non-
pigmented (cream colored) and slow- growers, i.e. only appearing three weeks 
after inoculation. The acidfastness was confirmed by Ziehl-Neelsen (ZN) 
staining procedure . 
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2.7.2.4. Isolation and Preservation Techniques 
2.7.2.4.1 Isolation 
All cultures were incubated in slope position for three days with loosen caps to 
evaporate the excess fluid then caps were closed tightly to prevent drying of 
media, placed in upright position and examined for contamination. Re-
examination was taken at first week to detect rapid growers and finally every 
week to detect slow growers up to the eighth weeks. The result was recorded  
as negative if no growth appeared, exact number if the colonies<20,20-100 was 
recorded as 1+, 2+ if the number of colonies is 100 to 200, 3+if the number of 
colonies is200-500, >500 is 4+(De Kantor et al 1998). 
2.7.2.4.2 Preservation 
Cultures were maintained through subculture on LJ medium and were stored in 
20% glycerol or in distilled water at -20 °C until used.   
2.8.Identification  
Isolates were   identified according to methods described by Kent and Kubica 
(1985). 
2.8.1 Primary Identification   
Isolates were identified according to growth rate and colonial morphology.  
2.8.1.1 Growth Rate  
0.1ml of bacillary suspension of each growers isolate was   inoculated on LJ 
slopes, incubated at 37 °C and examined after 5 to7days to identify the rapid 
growers by appearance of grossly visible colonies. 
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2.8.1.2 Colonial morphology 
The colonial morphology was described according the visual appearance of 
shape of colonies, size and elevation. 
2.8.1.3Pigment Production  
Mycobacteria synthesize carotenoid pigments in various amounts and kinds, 
depending upon the species and the exposure to the light. Using these 
variations in pigment production, the mycobacteria may be categorized into 
three groups: photochromogens, scotochromogens and nonphotochromogens. 
Four slopes of LJ medium were inoculated with 10-4 bacillary                                  
suspension,  two of them were covered with aluminum foil, incubated at 37°C, 
growth was examined for pigmentation in unshielded slopes, and shields were 
removed and examined for pigmentation and exposed to light for 5 hours, then  
the results were recorded. 
2.8.2.Biochemical Tests 
2.8.2.1.Catalase Test  
Catalase is an intracellular enzyme capable of splitting hydrogen peroxide into 
water and oxygen, 2H2O2 ? 2H2O+O2. The appearance of oxygen bubbles 
indicates catalase activity. Virtually all mycobacteria possess catalase enzymes, 
except for certain isoniazid resistant mutants of M .tuberculosis and M. bovis. 
2.8.2.2 Heat Stable Catalase Test at (pH7/680C)  
Isolates were suspended in 0.5 ml of 0.067M phosphate buffer saline with pH7, 
incubated at 680C in water bath for 20 minutes, cooled to room temperature 
and 0.5 ml of Tween-peroxide mixture was added and formation of bubbles 
was observed. Some bacteria lose catalase activity when suspended in a buffer 
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with pH7and heated to 680C for 20 minutes. Included in this group are M. 
tuberculosis, M. bovis, M. gastri and M. haemophilum. This hot catalase test is 
valuable in identifying strains of M. tuberculosis which give weakly positive or 
negative niacin test. All slow-growing non-chromogens mycobacteria were 
subjected to this test.  
2.8.2.3. Nitrate Reduction Test  
Isolates (consider age of the culture, temperature, enzyme inhibitors, and 
hydrogen ion concentration), were emulsified in 2ml NaNO3   substrate, 
incubated upright for two hours in a 370C water bath, removed then added the 
lame reagent and immediately examined for pink to red color. 
2.8.2.4.Para Nitro-benzoic Acid (PNB) 500mg/l Susceptibility Test 
0.1ml 10-2 bacillary suspensions were inoculated on two slopes of drug 
containing media and two slopes of drug -free media as a control, incubated at 
37 °C for 4 weeks and the proportion of growth was calculated.  
2.8.2.5Thiophen-2-carboxylic Acid Hydrazide (TCH) 5ug/ml Susceptibility 
Test  
bacillary suspensions(0.1ml of  10-2)were inoculated on to two slopes of drug 
containing media and two slopes of drug-free media as a control, incubated at 
37 °C for 4 weeks and the proportion of growth was calculated.This test is 
valuable for distinguishing M. bovis from M. tuberculosis and other 
nonchromogenic slow growing mycobacteria. Only M. bovis is susceptible to 
low concentration of TCH, 1 to 5ug/ml. isoniazid-resistant strain of M. bovis 
may be resistant to TCH. M. tuberculosis and other mycobacteria are usually 
resistant.  
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2.9. Susceptibility testing for Mycobacterium tuberculosis 
Part of the culture was inoculated on the media containing drugs. The 
remaining of the culture was stored at -20°C until used for PCR amplification 
(Kocagoz, et al 1993). 
The in-direct test was used for testing pure cultures of M.TB isolates. The 
number of Colony Forming Unit (CFU) on the drug -containing slant was 
compared with the number on control medium inoculated with similar 
dilutions. The breakpoint value of = 1% was used to classify the organisms as 
resistant (Bahremand, 1992 ) 
All isolates were cultured into Lowenstein-Jensen(L.J) medium for about 2-8 
weeks and then were tested for resistance to drugs, by   egg-base medium using 
proportion method. Briefly, appropriate concentrations of 
drugs(streptomycin(SM) 4.0ug/ml, two slopes containing rifampcin(RIF)40.0 
µg/ml, two slopes containing isoniazid (INH) 0.2µg/ml, two slopes containing 
ethambutol (EMB) 2.0 µg/ml, all bottles of media containing drugs were 
inoculated from suspensions with a concentration of 10- 2 in addition to two 
control media, were added to L.J medium, subsequently, L.J medium without 
(Control) and with drug were inoculated with 0.1 ml of 10- 2 and 10- 4 diluted 
suspension (The concentrations of the mother suspension were equal to 
McFarland No. 1.0 then followed by two dilutions of 10- 2 and 10- 4)of the 
isolate (each isolate)of M.tuberculosis. The inoculated bottles were then 
incubated at 37°C for up to 6 weeks. The isolates were considered susceptible 
to drug if the number of colonies grown on the drug-containing medium was 
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= 1% of the number of colonies grown on the drug-free control. An isolate was 
considered resistant if 1% or more grew on the drug-containing bottles. 
2.9.1 Preparation of Stock Solutions for Drugs  
2.9.1.1.Isoniazid  
Twenty mg of isoniazid (potency: 1gto1g) was dissolved in 40ml distilled 
water to provide 500µg/ml solution 2ml of this solution was diluted to 50ml to 
the 20µg/ml stock solution(Rieder et al 1998). 
2.9.1.2.Rifampicin  
Eighty mg /potency of rifampicin (potency: 980µg/mg)  was dissolved in 5ml 
of absolute methanol and further diluted with 5 ml of 95% ethanol to provide 
8,000.0ug/ml stock solution (self-sterilizing ) (Rieder et al 1998). 
2.9.1.3. Dihydro-Streptomycin Sulfate 
Forty mg of dihydro-streptomycin sulfate (potency: 667µg to 800ug/ml) was 
dissolved in 50ml sterile distilled water to provide 800µg/ml stock 
solution(Rieder et al 1998). 
2.9.1.4. Ethambutol 
Twenty mg of ethambutol powder (potency: 1g to1g) was dissolved in sterile 
distilled water to provide 200ug/ml stock solution (Rieder et al 1998). 
2.9.2 Preparation of Drug Containing Media 
Five ml of isoniazid stock solution was added to500ml of the LJ medium to 
provide 0.2ug/ml critical drug concentration, 2.5 ml of rifampicin stock 
solution was added to 500ml of L J medium to provide 40ug/ml critical drug 
concentration, 5ml of streptomycin   stock solution was added to 500ml of L J 
medium to provide 8ug/ml critical drug concentration and   5ml of ethambutol 
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stock solution was added   to 500ml L J medium to provide 2ug/ml critical 
drug concentration. The media were inspissated at 85°C 0C for 15 minutes, 
checked for contamination and stored at refrigerator (4°C).  
2.9.2.1. PNB 
PNB (0.2g )was dissolved in 15ml sterile distilled water and 2ml of 1N NAOH, 
neutralized with HCL 1N containing phenol red as indicator, end point was 
determined  and the volume was completed to 20ml and each 5 ml of drug was 
added to 100ml of L J medium, dispensed, and insipissated in slopes position. 
2.9.2.2. TCH 
Twenty five mg of TCH was dissolved in 20ml distilled water in water bath  
450C for 30 minutes and each 4 ml of drug  was  added to 1000 ml L J medium, 
dispensed  and insipissated in slopes  position.    
2.9.3. Quality Control of Prepared Media   
 Every new batch of drug containing media was inoculated with 
Mycobacterium tuberculosis H37Rv sensitive strain to ensure the critical 
concentration of the drug contained in the media.  
 
2.9.4.Preparation of Bacillary Suspension   
The colonies were subcultured for 1 to 2 weeks,  and  placed into McCartney’s 
bottle containing 1ml of sterile distilled water and 6 to 8 glass beads using an 
inoculating loop, homogenized on a vortex mixer   for up to 1 minute, the 
opacity of the suspension was adjusted by addition of sterile distilled water to 
that of McFarland No.1. 
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2.9.5. Preparation of McFarland’s Solution  
One percent solution of anhydrous barium chloride (BrCL2) and a 1 %( v/v) 
cold solution of pure sulfuric acid were prepared, 0.1 ml of 1% BaCL2 was 
added to 9.9ml of 1% H2SO4 to prepare McFarland No.1 tube. 
2.10. Molecular analysis 
2.10.1. DNA extraction 
A loopful from the colonies was boiled for 10 min in 400 µl of distilled water 
to kill the mycobacteria as described by Takewakiet al(1993). DNA was 
extracted using Bioneer Kit (Cat. No3032).This procedure was performed 
according to the instructions of the manufacturer as follows: 20µl of protienase 
k was added to a clean 1.5ml tube.Then 200µl of a suspension of 104-
108CFUwere added to the tube containing protienase k and the 200µl of 
binding buffer (GC) were also added to the same tube and incubated at 60°Cfor 
10 min, 100µl of isopropanol were added and the tube content was mixed well 
by pippetting. The lysate was carefully transferred into the upper reservoir of 
the binding column tube (fit in a 2ml tube) without wetting the rim. The tube 
was closed and centrifuged at 8000rpm for 1 minute, after centrifugation the 
tube was opened and   the binding column tube was transferred to a new 2ml 
tube for filtration. Then 500µl of washing buffer 1 (W1) were added without 
wetting the rim, and the tube was closed and centrifuged again at 8000 rpm for 
I minute, then the supernatant was discarded. 500µl of washing buffer 2(W2) 
were added and centrifuged at the same speed (8,000 rpm) for 1 minute, then 
centrifuged once more at 12000 rpm for 1 min to remove the ethanol 
completely, and confirmed that there is no droplet clinging to the bottom of the 
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binding column tube. The binding column tube was transferred to a new 1.5ml 
tube for elution.  200µl of Elution buffer were added (EL buffer,or nuclease-
free water) to the binding column tube and left for at least 1 min at RT(15-
25°C) until EL buffer was completely absorbed into the glass fiber of the 
binding column tube. 
2.10. 2. Duplex polymerase chain assay (DPCR) 
The followingOligonucleotide primers(primer sets) were used: 
Tbc1: 5? -CGT ACG GTC GGC GAG CTG ATC CAA-3?  
TbcR5: 5? -C CAC CAG TCG GCG CTT GTG GGT CAA-3?   
M5: 5? -G GAG CGG ATG ACC ACC CAG GAC GTC-3?  
RM3: 5? -CAG CGG GTT GTT CTG GTC CAT GAA C-3?  
(Kim et al 2004) 
2.10.2.1. Procedure 
Four µl of primers (10 pmol of Tbc1-TbR5 and 20 pmol of M5-RM3) and 2 µl 
of template DNA were added to a PCR mixture tube (AccuPowerTM PCR 
PreMix; Cat No. 2010 Bioneer, Daejeon, Korea) containing 1 U of 
Taqpolymerase, 250 µM each deoxynucleoside triphosphate, 10 mMTris-HCl 
(pH 9), 30 mMKCl and 1.5 mM MgCl2. DNAase, RANase free sterile double 
distilled water was added to a final volume of 20 µl per reaction mixture. The 
mixture was vortexed and transferred to PCR thermocycler. The protocol was 
performed with an initial denaturation of 95°C for 5 min, 30 cycles of 
amplification (30 sec at 95°C, 60 sec at 72°C), and a final elongation at 72°C 
for 5 min. An amount of 5 µl of PCR product were loaded and visualised by 
Please purchase PDFcamp Printer on http://www.verypdf.com/ to remove this watermark.
 80
electrophoresis at 85 V for 60 minutes on 1.5% agarose gel with 0.5 mg/ml of 
ethidium bromide in 1% Tris-Acetate-EDTA (TAE) buffer and photographed. 
2.10.3.MultiplexPCR assay  
Oligonucleotide primers used 
CSB1: 5? -TTCCGAATCCCTTGTGA-3?  
CSB2: 5? -GGAGAGCGCCGTTGTA-3?  
CSB3: 5? -AGTCGCCGTGGCTTCTCTTTTA-3?  
(Bakshiet al 2005) 
2.10.3.1.Procedure 
Three µl of primers (10 pmol of each) and 2 µl of template DNA were added to 
a PCR mixture tube (AccuPowerTM PCR PreMix; Cat No. 2010 Bioneer, 
Daejeon , Korea ). DNAase, RANase free sterile double distilled water was 
added to a total volume of 20 µl. The mixture was vortexed and placed into 
PCR machine. The thermocycling parameters included an initial denaturation 
at 94 °C for 5 minutes, followed by 30 three-step cycles, including 
denaturation at 94°C for 1 minutes, annealing at 52.3°C for 1.5 minutes, 
extension at 72°C for 1 minutes and a final extension at 72 °C for 5 minutes. 
The PCR products (5 µl) were loaded and visualised by electrophoresis at 85 V 
for 60 minutes on 1.5% agarose gel with 0.5 mg/ml of ethidium bromide in 1% 
TAE buffer and photographed. 
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2.10.4.Molecular detection of  drug resistance 
2.10.4.1.Multiplex allele-specific PCR(MAS-PCR) 
Six allele-specific primers corresponding to the 6 codons targeted and 4 
primers paired respectively with 1–3 of the 6 allele-specific primers were used 
in the MAS-PCR assay (Table 1). For each MAS-PCR reaction, a standard 
50µL reaction mixture was used. Each reaction mix includes 10 primers: 
rpoB516 (10 pmol in 1µL), rpoB526 (5 pmol in .5 µL), rpoB531 (15 pmol in 
.15 µL), RIRm (30 pmol in 3 µAL), katgOF (2 pmol in 0.2 µL), katg5R (2 
pmol in 0.2 µL), inhAP-15 (3 pmol in 0.3 µL), inhAPF (3 pmol in 0.3 µL), 
embB306 (1.5pmol in 0.15µL), and embBR (1.5 pmol in 0.15µL). The other 
reagents included in each reaction mix were 1 µL of 50_deoxyribonucleotide 
mix, 2.5 µL of 10×  reaction buffer, 0.5 µL of 50_ BD AdvantageTM2 
Polymerase Mix, 2 µL DNA solution containing 40 ng DNA template,1µL 50 
mM MgCl2 and 11.2 µL PCR-grade water. The thermocycling parameters 
included an initial denaturing at 96 °C for 1 min, 30 cycles of 95 °C for 50 sec, 
54 °C for 40 sec, and 72 °C for 40 min and a final extension at 72 °C for 7 min. 
The PCR products were examined for the banding patterns by 2.5% agarose gel 
electrophoresis in 1× Tris-Borate-EDTA buffer. The PCR product (5µL) were 
loaded and visualized by electrophoresis at 85V for 90 minutes on 2.5 % 
agarose gel with 0.5 mg/ml of ethidium bromide in 1% TAE and photographed. 
The accuracy of a MAS-PCR results  will be based on the results of  proportion 
method  used, egg based Lowenstein-Jensen medium, the medium containing 
drugs (RIF and INH and EMB) for DST of M. tuberculosis, as standardized 
method (Gold standard method). The accuracy of the test was defined as its 
Please purchase PDFcamp Printer on http://www.verypdf.com/ to remove this watermark.
 82
capacity to identify true resistant and true susceptible strains of M. tuberculosis 
as determined by the standard proportion test (Yang et al 2005). 
Table 1.Primers for MAS-PCR to detect INH, RIF, and EMB resistance 
mutations of M. tuberculosis 
Detecti
on 
targets 
Allele-specific primers (5V–
3V) 
Paired primers Lengt
h of 
PCR 
produ
ct 
(bp) 
katG31
5 
katG5Ra         
ATACGACCTCGATGCCG
C 
katGOFa 
GCAGATGGGGCTGATCT
ACG 
292 
mabA-
inhA: 
_15 
InhAP-15 
GCGCGGTCAGTTCCACA 
inhAPF2 
CACCCCGACAACCTATC
G 
270 
rpoB51
6 
rpoB516 
CAGCTGAGCCAATTCAT
GGA 
RIRm 
TTGACCCGCGCGTACAC 
 
218 
rpoB52
6 
rpoB526 
CTGTCGGGGTTGACCCA 
 
rpoB53
1 
rpoB531 
CACAAGCGCCGACTGT
C 
170 
embB3
06 
embB306 
GGCTACATCCTGGGCAT
G 
embBR2 
GAGCCGAGCGCGATGA
T 
170 
(Yang et al 2005) 
2.11. HIV Diagnosis 
HIV-1 testing consists of initial screening with an enzyme-linked 
immunosorbent assay (ELISA) to detect antibodies to HIV-1/HIV-2. 
Specimens with a nonreactive result from the initial ELISA were considered 
HIV-negative. Specimens with a reactive ELISA result were retested in 
duplicate. If the result of either duplicate test was reactive, the specimen was 
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reported as repeatedly reactive and undergoes confirmatory testing with 
anotherkit . 
2.11.1. Procedure 
2.11.1.1. Genscreen ULTRA HIV Ag-Ab 
The negative (R3), HIV-1Ab positive (R4) and HIV (R5) controls for each 
series of determinations to validate the test results was used (Appendix IV). 
1- The sample distribution and identification plane was carefully 
established. 
2-  The diluted washing solution was prepared. 
3-  The conjugate 2 washing solution was prepared. 
4-  The carrier tray and strips (R1) was taken out of protective pouch. 
5-  Without prior washing of the plate and in succession   
 5-1 25µl of conjugate 1(R6) in each well 
 5-2 75ulof HIV Ag positive control (R5) in well A1  
 75ul of HIV Ab positive control (R4) in well B1 
 75ul of negative control (R3) in well C1, D1 andE1 
 75ul of specimen 1 in well f1 
 75ul of specimen 2 in well g1…..etc… 
 was applied directly and the mixture homogenized by a minimum 
of 3 aspirations with 75ul pipette or by shaking the micro plate 
after the pipetting step. 
6-  When possible the micro plate was covered with adhesive film. Pressed 
firmly all over the plate to ensure a tight seal. 
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7- The micro Plate was Incubated in a thermostat –controlled water- bath or 
micro plate incubator at 370c ± 1°C for 1 hour ± 4 minutes. 
8-  The adhesive film was removed and the  contents of all wells were 
aspirated into a container for biohaziardous  waste (contain sodium 
hydrochloride).add into each well a minimum of 0.370 ml of washing 
solution .allow a soak time at least 30 seconds .aspirate again. Repeat this 
procedure a minimum of two times. The residual volume was lower than 
10 µl. 
9-  100ul of conjugate 2 solutions was quickly dispensed (R7a +R7b) into all 
well, the conjugate must be shaking before use.        
 10- The plate was covered with new adhesive film and incubate for 30 
minutes ± 4 minutes at room temperature (18-300c). 
11-  The adhesive film was removed, all wells were empty by aspiration and 
wash a minimum for 5 times as described above. The residue volume 
must be lower than 10 µl. 
12-  Into each well 80ul of prepared substrate solution was quickly dispensed 
(R8+R9), freshly prepared before use .allow the reaction to develop in 
the dark for 30+_4 minutes at room temperature (don’t use adhesive film 
during this incubation). 
13-  100ul stopping solution was added (R10) by using the same sequence and 
rate of distribution as for the substrate solution. 
14- The plate was wiped carefully for 2 minutes after the addition of stopping 
solution and within 30 minutes of stopping the reaction, the optical 
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density was read at 450/620-700nm using a plate reader within 30 
minutes of stopping the reaction. 
15-  Between the spectrophotometric and visual reading and against the plate 
and sample distribution and identification plates was check for 
agreement.     
2.11.1.2. Calculation and Interpretation of the Results  
The presence or absence of detectable HIV antigen or antibodies to HIV1 and 
/or HIV2 was determined by comparing the absorbance measured for each 
sample to calculate cut off value  
2.11.1.2.1. calculation  the mean absorbance of the negative control 
 Mean of Optical density of negative control (ODR3)=OD (C1)+OD(D1) 
+OD(E1)/3 
2.11.1.2.2.Calculate the cut off value  
Cut off valuewas given by the formula: 
CO= mean of OD R3+0.200 
2.11.1.2.3. Assay validation 
The absorbance of each negative control (R3) was less than 
0.170:ODR3<0.170. 
If one negative control didn’t respect this norm, disregard and recalculate the 
mean using the two remaining values. Only one value may be eliminated by 
this way: 
The mean of absorbance of negative controls (R3) was less than 0.150: OD< 
0.150  
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The absorbance of HIV Ab positive control (R4) was greater than 0.9: OD 
R4>0.9  
The absorbance of HIV Ag positive control (R5) was greater than 0.9: OD 
R5>0.9  
2.11.1.2.4.Interpretation of the results 
Samples with absorbance values less than the cut off value were considered to 
be negative by the GenscreenTM  ULTRA HIV Ag –Ab test. 
Results just below the cut off value (C.O-10%< OD <C.O), was interpreted 
with caution (it is advisable to retest in corresponding samples when the 
systems and laboratory procedures permit). 
 Samples with absorbance value equal to or greater than the cut off value were 
initially considered to be positive by the GenscreenTM  ULTRA HIV Ag –Ab 
test. They were retested in duplicate before final interpretation. 
If after retesting of a sample, the absorbance value  of the 2 duplicates were 
less than the cut off value, the initial result was non repeatable and the sample 
declared to be negative with the GenscreenTM  ULTRA HIV Ag –Ab test. 
Non reputable reactions were often caused by: 
· Inadequate micro plate washing  
· Contamination of negative samples by serum or plasma with highly 
antibody titer. 
· Contamination of substrates solution by oidising agents. 
· Contamination of stopping solution. 
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If after retesting the absorbance of one of the duplicates was equal to or greater 
than the cut off value, the initial result was repeatable and the sample was 
declared to be positive with the GenscreenTM  ULTRA HIV Ag –Ab test(BIO 
RAD 010059). 
2.11.1.2. Vironostika HIV Ag/Ab 
1-  the strip holder was fitted with the required number of Microelisa strips. 
2-  100ul specimen dilute into all well, including control wells. 
3-  50ul sample or control into assigned wells, included the three negative 
controls, one anti-HIV-1positive control, one anti-HIV-2positive control 
and one HIV-1 antigen positive control in each strip holder. Always was 
pipetted the controls after pipetting the samples. any unused wells was 
Fill with specimen diluent in order to dissolve the conjugate sphere and 
prevent malfunction of the aspiration/wash system. 
4- Using micro shaker well was mixed, speed approximately 15 Hz for 15 
second or equivalent. the strips was Incubated at 370c for 60 ± 5 minutes. 
5-  each well six times was washed and soaked with phosphate buffer  
· Incomplete washing well adversely affect the assay outcome. 
· The well contents were aspirated completely into waste flask. Then 
fill the well completely with phosphate buffer avoiding overflow 
from one well to anther and allow to soak for 30 to 60 seconds. 
Aspirate completely and repeat the wash and soak procedure five 
times for total of six washes. 
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· To wash the wells It was preferable by filling them with a fluid 
volume greeter than the well  volume while simultaneously 
aspirating excess volume in order to prevent overflowing  
· Any remaining fluid on the top and bottom of the microelisa strips 
was removed and strip holder after the last aspiration by blotting 
with absorbent tissue.          
6-  100ul TMB substrate into each well. Didn’t not mix or shake. 
7-  The strips was Incubated at 15 to30 0c for 30 ± 2 minutes in the dark. 
8-  The reaction was stopped by adding 100ul 1mol/1 sulfuric acid to each 
well; use the same pipetting sequence and time intervals used for TMB 
substrate addition. Ensure thorough mixing by tapping the side of the 
strip holder. Plates were read within 15 minutes. 
9-  Blank the reader on air, without strip holder and stripe, and the 
absorbance of the solution was read in each well at 450nm and 620 to 
700nm as reference (dual wave length). 
 
2.11.1.2. 1.Results 
2.11.1.2. 1.1.Manual calculation 
Calculation was made separately for each strip holder. 
NC  = absorbance of the negative control  
PC1 = absorbance of the anti- HIV-1positive control 
PC2 = absorbance of the anti- HIV-2positive control 
PC3 = absorbance of the HIV-1 antigen positive control 
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2.11.1.2. 1.2.Qualification of the NC values 
1  NC was < 0.250. Eliminate any NC =  0.250. 
2  determine the men (NCx) value of the remaining controls. 
3  NC was = 1.4NCx. Eliminate any NC>1.4NCx and recalculate NCx. 
4  NC was = 0.6NCx.Eliminate any NC< 0.6NCx recalculate NCx. 
5  Steps 3 and 4 repeated till no more outliers were found. 
2.11.1.2. 1.3.Assay validity  
An assay run was valid if  
1  more than half the number of the negative controls remain; 
2  PC1 -NCx= 0.600 
3  PC2 - NCx= 0.600 
4  PC3 - NCx= 0.400 
2.11.1.2. 1.4.Cut-off value  
If the test run was valid, the cut-off value was calculateNCx+0.100. 
A test sample was reactive if sample was = cut-off value. 
A test was nonreactive if sample was < cut-off value.  
2.11.1.2. 1.5.Interpretation of results  
· A nonreactive result indicated that the sample tested either didn’t  contain 
anti -HIV-1, anti -HIV-2, anti -HIV-1 group O or HIV-1 antigen  or that 
the  sample contains one or more of these blew the detection limit of the 
Vironostika HIV Ag/Ab assay. 
·  A reactive result indicated  that the sample tested either contain anti -
HIV-1, anti -HIV-2, anti -HIV-1 group O or HIV-1 antigen or that it 
contained a nonspecifically reaction factor. 
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· Specimens that showed an initially reactive result was retested I 
duplicated. An only specimen reactive in one or both retests was 
considered reactive for anti-HIV-1, anti-HIV-2, and anti-HIV-1 group O 
and/or HIV-1antigen. 
Initially reactive specimens that were nonreactive in duplication testing, was 
considered nonreactive(BiomerieuxA61CC). 
2.12. Statistical analysis 
Data analysis was performed using SPSS version 16.Results were cross-
tabulated to examine the relationships among variables. Statistical analysis was 
performed using the X2test for tests of association. For all tests a P value of 
less than 0.05 was considered significant. 
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CHAPTER THREE 
RESULTS 
3.1. Study population  
Two hundred and fifty two new cases of TB patients participated in the current 
study, depending on the microscopical examination of their sputa. All of them 
were smear positive when stained by ZN stain. 
3.2. HIV status among tuberculosis patients 
Twenty five (10%) out of 249 TB patients showed positive reaction to HIV.19 
(10.8%) out of 176 patient were males  who were reactive to HIV, while 
six(7%) out 76 female were reactive to HIV.There was no significant 
association between gender and HIV status (P = 0.06) (Fig.1). 
3.3. Epidemiological data of the study subjects 
3.3.1. Age groups  
Two hundred and fifty two patients with the age range from 14- 65 years 
(mean31.86) were included in this study. The distribution of the tuberculosis 
among different age groups is shown in Fig 2.  
3.3.1.1. Age and HIV  
Table 2 illustrates the distribution of age groups among HIV positive and 
negative patients.  
3.3.2. Gender  
One hundred and seventy six (70%) of 252 patients were males while 76(30%) 
were females. 
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3.3.2.1. Gender and HIV status 
Out of 176 male TB patients nineteen(10.8%) were HIV positive while six out 
of 76(8 %) female showed positive reaction, on the other hand one male(0.4%) 
and two females (0.8%) refused to be tested for HIV. 
3.3.3. Infection among smoker and alcohol drinkers 
Seventy seven (30.5%) male were smokers, while only four (1.6%) females 
were smokers. Statistically there was significant correlation between infection 
and smoking (P = .000). 
Thirty one (12.3%) male were alcoholics, on the other hand only two women 
(0.8%) were alcoholics. Statistically there was significant correlation between 
infection and alcohol (P =  .001). 
3.3.4. Marital status among the study population 
Fig 3 shows the distribution of marital status among pulmonary tuberculosis 
patients. 
3.3.4.1. Marital status and HIV status  
Thirteen(9.2%) out of one hundred and forty one married tuberculosis patients 
infected with HIV, 11(10.7%) out one hundred and three tuberculosis single 
patients were reactive for HIV, more details are shown in table 3. 
3.3.5.Residence 
Two hundred and forty three patients (96.4%) lived inside Khartoum state 
while only nine patients (3.6%) were outside Khartoum state. 
3.3.6. Tribes according to the area of origin 
In spite of the fact that most patients were permanent in Khartoum but really 
they originate from different parts of Sudan. It was found that, out of 252 
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patients, the highest percentage was 64(25.4%) from kordofan, followed by 
Algazira, white  nile  and Sinnar45(17.9%);the rest of the areas are shown in 
Fig 4. 
3.3.7. Educational level 
Among the study group 65(25.8%) patients were illiterate while the remaining, 
vary in their education  from khalwa to higher education, Fig 5 shows the 
distribution  of pulmonary tuberculosis according to their education 
levels.96(38.1%)  primary school, 65 (25.8%) secondary, and 11  (4.4%)  were 
at university, and 12 (4.8%) khalwa and 3 (1.2%) were mahoalomia.No 
significant correlation between education and infection (P= o.59). 
3.3.8. Occupation 
Out of 252 patients,21(8.3%) were employee,16(6.3%) workers,88(34.9%) had 
free work (simple work),2(0.8%) were retired, while 89(35.3%)out of 
work,26(10.3%) students at different level of education including university 
and 10(4%) represented other types of occupation (5 of them faki and the 
others were in  herbal therapy) .There were no statistically significant 
correlation between occupation  and  infection (P = 0.475) . 
3.4. Clinical symptoms 
The frequency of symptoms among the Tb patients distributed as follows: 
Patients who revealed no symptoms were 11(4.4%), cough 194(77%), 
heamptosis1 (0.8%), cough and chest pain 14(5.6%) and cough, chest pain and 
heamptosis30 (11.9%). 
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3.5. Microscopical examination  
Direct microscopic examination was done to 252 sputum specimens using Z.N. 
staining procedure. The examined specimens showed the characteristic AFB 
appearance of serpentine cords under the oil immersion fields  they were 
considered as the true positive. 
3.6. Culture on Lowenstein Jensen medium 
All sputum specimens (252) that collected from TB patients were cultured on 
LJ media and pyruvate media, after incubation period that ranged from one 
week to eight weeks, 241 (95.6%) revealed growth of rough colonies, friable, 
non pigmented colonies and the incubation temperatures ranged from 35oC to 
37oC within two to five weeks while one sample showed growth after one 
week, 11 (4.4%) showed no growth or contamination after eight weeks. 
3.7. Biochemical Analysis 
3.7.1. Susceptibility testing to PNB and TCH  
Two hundred and forty one fresh suspension of clinical isolates were 
inoculated in L.J. media containing PNB and other bottles of LJ media 
containing TCH and incubated for one month at 35-37oC, after examination 
period all clinical isolates showed no growth on media containing PNB while 
all clinical isolates showed growth in TCH except two isolates showed no 
growth in TCH. 
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3.7.2. Catalase test at 68 0C 
Labile Catalase test, which was done for 241 isolates, showed negative result 
for 238 isolates, which considered as MTBC. The remaining three isolates 
which showed positive results were considered as MOTT. 
3.7.3. Nitrate reduction test 
Out of 241isolates, 237 isolates produced pink color, which was the indicator 
of positive results, while four of them were considered as negative because no 
color was produced, and by the addition of zinc dust the pink color developed 
confirming the negative results. The positive result indicated that the isolate 
might be M. tuberculosis, M. microti, or M. africanum, while the negative 
result was related to M. bovis. 
3.8. Molecular identification 
The technique DPCR assay method was performed to identify 241 clinical 
isolates. Out of the 241culture isolates examined, 235 strains were identified as 
M. tuberculosis complex which produced 235-bp amplicons and the other 6 
strains which produced 136 bp amplicons were identified as NTM (Fig 6, Fig 
7). These results were completely concordant with those obtained by 
conventional culture testing. 
3.8.1. HIV and type of growth 
Twenty five patients were reactive for HIV, 18 of them had typical 
mycobacterial complex, three were atypical mycobacteria, four showed no 
growth (Table 4). 
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3.9. Drug susceptibility 
Drug sensitivity tests were done for 241 clinical isolates using proportion 
method .235 out of them were typical mycobacterium complex (MTC).Forty 
six percentage of MTC were resistant to one or more of the drug tested, Fig 8 
illustrates the results of the drug susceptibility testing to the 1st line of anti-
tuberclus drugs, while the other six clinical isolates were atypical 
mycobacteria, all of them showed resistance to all of the above mentioned 
antituberclus drugs. Mono-resistance to the four first line anti-tuberculosis 
drugs was shown as follows: 4(1.7%) rifampcin, 5(2.1%) isoniazid, 41(17.4%) 
streptomycin, and 7(3%) ethambutol.  
Based on the phenotypic drug susceptibility testing results, 18(7.7%) of the 235 
typical Mycobacterium of study isolates were identified as MDR. Of the 
remaining 217 isolates, 15 were non–MDR-INH resistant including five 
isolates INH mono resistant, 15 were non–MDR-RIF-resistant including four 
isolates RIF mono resistant, and 127 were pan sensitive. 
A total of 46 EMB-resistant isolates were identified in the study sample 
including 7 had mono resistant. Of theses 46 EMB-resistant isolates, 13 
belonged to the MDR group, 6 had simultaneously INH resistance, 8 were also 
resistant to RIF and 12 were belong to SM-resistant in addition to resistant to 
EMB ,and also 41 isolates showed  mono resistant to SM .The patterns of the 
drug resistance of the clinical isolates are shown in table 5. 
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3.9.1. HIV and Drug resistance 
Eighteen out of two hundred thirty five (7.7%) of patients were found to be 
HIV positive, and the drug resistance patterns for HIV positive patients are 
shown in table 6. 
3.10. MAS-PCR 
The MAS-PCR showed different patterns of bands illustrate the expected 
codons associated with the mutations. The banding pattern revealed the 
following expected mutations; 21(8.9%) for KatG gene,4(1.7%) for inhA-15 
gene, these for isoniazid. For rifampicin, the following mutation were detected; 
21(8.9%) for rpoB531,7(3%) for rpoB526 and 2(0.9%) for 
rpoB516.Moreover,56(23.8%) were for emb306 gene that encode for 
ethambutol resistance (Fig.9 and Fig.10). 
3.10.1. Sensitivity and specificity 
The sensitivities and specificities of the MAS-PCR for INH, RIF, and EMB 
resistance were assessed, respectively, using culture results as reference. Table 
7 illustrates the details of comparison between conventional drug susceptibility 
results and the obtained results by multiplex allele specific –PCR. Out of the 18 
culture-proven MDR isolates, 13(72.2%) were identified as MDR by MAS-
PCR, genetic mutations associated with rpoB gene were as follow rpoB531 
11(84.6%), rpoB526 1(7.7%) and rpoB 516 1(7.7%).216(99.5%) of 217 non-
MDR isolates defined by culture were classified as non-MDR isolates by 
MAS-PCR. Thus, the sensitivity of the MAS-PCR assay for MDR detection 
was 72.2% and the specificity was 99.5%. 
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Of the 33 isolates that were INH resistant by culture, 24 were identified as 
INH-resistant, 21(87.5%) have mutation associated codon 315 katG gene and 
four (16.6%) at codon inhA-15, resulting in a detection sensitivity of 73 %. The 
specificity of MAS-PCR for INH resistance was 99.5 %, proved 201 of the 202 
isolates that were susceptible to INH by culture showed the expected wild-type 
allele-specific patterns. One of the 202 non–INH-resistant isolates showed a 
mutant pattern for the 315 position of the KatG gene region by MAS-PCR. For 
RIF resistance detection, the sensitivity of MAS-PCR assay was 87.87 % with 
the identification of 29 of the 33culture-proven RIF-resistant isolates, genetic 
mutation associated with codons rpoB531 were 21out of 29(72.4%),rpoB526 
were 7(24%) and rpoB 2(6.9%). Of the 202Culture-proven RIF-susceptible 
isolates, 1 showed a MAS-PCR pattern of a resistant strain, producing a 
specificity of 99.5 % for RIF detection. 
In case of EMB 46 isolates were found resistant by culture, of which 31 were 
identified as EMB-resistant by MAS-PCR.MAS-PCR detection sensitivity was 
67.4 %, while the specificity was 86.8 %. Furthermore; 164 of the 189 isolates 
that were susceptible to EMB by culture showed the expected wild-type allele-
specific patterns. 
The discordant results between proportion (culture) and MAS-PCR in concern 
resistance were as follow, of 33 INH resistant isolates by culture, 9 of them 
failed to generate the expected banding patterns by MAS-PCR, also 4 of 33 
rifampcin resistances were showed discordant results in concern MAS-PCR. 
Fifteen out of 46 EMB phenotypically resistant isolates revealed no expected 
banding patterns of MAS-PCR. 
One of 202 INH, RIF susceptible isolates and 25 of 189 susceptible isolates 
showed unexpected results of banding patterns  
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Fig. 1:  HIV status among Tuberculosis patients 
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Fig. 2: Distribution of pulmonary tuberculosis among different 
age groups 
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Fig. 3: Distribution of marital status among pulmonary 
tubercles patients 
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Fig. 4: Distribution of pulmonary tuberculosis according to the 
area of origin 
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Fig. 5: Distribution of pulmonary tuberculosis according to 
education level 
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Fig.6 Results of differentiation of Mycobacterium tuberculosis complex and 
Non Mycobacterium tuberculosis by a single tube Duplex-PCR 
Results of DPCR assay on agarose gel electrophoresis, two amplicons of 
different size were amplified, 235bp band represents M tuberculosis complex 
and 136 bp band represents NTM. Lane M  represents 100 bp ladder, lane 1 is 
H37RV,lanes 3,5,6,8,9,10,12,14 and 15 represent different clinical isolates of 
M tuberculosis complex, lane 2 positive control strain of NTM, lane 11 
negative control, lanes 4,7 and 13 different clinical isolates of NTM. 
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Fig.7 Results of differentiation of Mycobacterium bovis and Mycobacterium 
tuberculosis by a single tube multiplex-PCR 
In multiplex-PCR two amplicon of different size  amplified on agarose gel 
electrophoresis.262 bp represents M. tuberculosis and 168 bp for M. bovis 
Lanes: (M) DNA molecular mass marker (100 bp ladder);  Lane 1,M. 
tuberculosis H37Rv, lanes 2 to 10,14 and 15 were clinical isolates of M 
tuberculosis, lane 11 control negative, Lane 13M.bovis  . 
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Fig. 8: Results of Drug susceptibility testing 
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    Fig.9 Results of MAS-PCR .Results of MAS-PCR shown by 2.5 % agarose 
gel electrophoresis. The 335-bp band represents the embB codon 306-specific 
PCR product; the 292-bp band, represents the katG codon 315-specific PCR 
product; the 270-bp band, the _15 promoter region of mabA-inhA–specific 
PCR product; 218-bp band, represent rpoB codon 516-specific PCR product; 
185-bp band represents rpoB codon 526-specific PCR product; and the 170-bp 
band, rpoB codon 531-specific PCR product. Lane 1 represents the 100-bp 
DNA ladder. Lane 2 represents the reference strain H37Rv; lanes 3, 4, and 
5,represent  clinical isolates that had no mutation at any of the codons or region 
investigated: The remaining represent isolates that expected had of mutation(s): 
at lane 6 katG codon315 and rpoB codon 516 ,lane 7 katG codon 315 and rpoB 
codon 526, lane 8 rpoB codon 531  ,lane 9 KatG codon 315 and rpoB codon 
531,lane 10 and 11 (katG codon 315, rpoB codon 516 and rpoB codon 
531),lane12(embB codon 306 and rpoB codon 516), lane 13(embB codon 306 
,KatG codon 315 and rpoB codon 516 ),lane 14(embB codon 306 ,katG codon 
315, and  rpoB 531) , lane 15 control negative. 
Please purchase PDFcamp Printer on http://www.verypdf.com/ to remove this watermark.
 108
 
 
Fig. 10 The frequency of banding patterns illustrate 
 the mutant genes 
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Table  2 Age group and HIV status  
 
 
HIV status 
Total negative positive Refused 
agp 1-14 4 0 0 4 
15-24 59 7 0 66 
25-34 77 8 1 86 
35-44 50 6 0 56 
45-54 18 3 1 22 
55-64 14 1 1 16 
65 or 
more 
2 0 0 2 
Total 224 25 3 252 
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Table 3 marital status and HIV status  
 
 HIV status 
 
marital status Total 
married Single divorce widow others  
 negativ
e 
126(50%) 
91(36.1
%) 
3 2 2 224 
 positive 
13(5.1%) 
11(4.4%
) 
0 0 1 25 
 refused 2(0.8%) 1(0.4%) 0 0 0 3 
Total 141(55.9
%) 
103 3 2 3 252 
 
Table 4 Type of growth and HIV status 
Type of 
growth 
HIV status Total 
Negative positive refused 
Typical MTB 
Atypical 
MTB 
Not available  
Total 
214 
3 
7 
224 
18 
3 
4 
25 
3 
0 
0 
3 
235 
6 
11 
252 
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Table 5 Patterns of drug resistance of the studied mycobacterium isolates 
Drug 
Frequency of resistance 
isolates Percent 
 INH+RIF 4 1.7 
 INH+RIF+SM 1 .4 
 INH+RIF+EMB 1 .4 
 INH+RIF+SM+
EMB 
12 5.1 
 INH+EMB 4 1.7 
 INH+SM 4 1.7 
 INH+EMB+SM 2 .9 
 RIF+EMB 4 1.7 
 RIF+SM 3 1.3 
 RIF+EMB+SM 4 1.7 
 SM+EMB 12 5.1 
 INHmono 5 2.1 
 RIFmono 4 1.7 
 SMmono 41 17.4 
 EMBmono 7 3.0 
 sensitive ALL 127 54.0 
 Total 235 100.0 
Missin
g 
System 
17  
Total 252  
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Table 6 Drug resistance and H IV status 
 
 
 
 
 
 
 
 
 
 
 
 
 
Drug resistance HIV status Total 
negative positive  
INH+RIF+SM+EMB 9 3 12 
RIF+EMB+SM 3 1 4 
SM+EMB 10 2 12 
INHmono 4 1 5 
RIFmono 3 1 4 
SMmono 39 1 41 
sensitiveALL 116 9 127 
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Table 7: Comparison between Conventional drug susceptibility testing and MAS-PCR (concordant and discordant and the gene 
associated to MAS-PCR) and sensitivity and specificity of MAS-PCR 
 
 
Drug     Resistant strains Susceptible strains 
C
onventional-(culture –
base) 
 M
A
S-PC
R
 C
oncordant 
w
ith conventional  
RpoB codons- RIF 
(MAS-PCR) 
INH codons 
(MAS-PCR) 
EM
B
 
(M
A
S-PC
R
) 
Sensitivity of M
A
S-
PC
R
  
D
iscordant 
(susceptible by 
M
A
S-PC
R
) 
Susceptible strains by 
culture  
Susceptible by   M
A
S-
PC
R
(concordant w
ith 
M
A
S-PC
R
) 
D
iscordant 
(resistant  by M
A
S-PC
R
) 
Specificity of M
A
S-PC
R
  
Codon 
531 
Codon 
526 
Codon 
516 
KatG   
315 
inhA-15 embB 
306 
MDR Non-
MDR 
MDR 
At least 
RIF+INH 
18 13 11 
(84.6%) 
1  
(7.7%) 
1  
7.7% 
11(84.6%) 2 
(15.4%) 
- 72.2%  5  
27.8% 
- - - - 
RIF *33 29 20 
69% 
7  
24% 
2 
7% 
- - - 87.87% 4 
12.12% 
202 201 1 99.5% 
INH *33 24 - - - 20  
83.3% 
4 
16.7% 
- 73% 9  
27% 
202 201 1 99.5% 
EMB *46 31 - - - - - 31 67.4% 15  
32.6% 
189 164 25 86.7% 
 
*Include all types of resistance
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CHAPTER FOUR 
DISCUSSION  
Sudan was one of the largest countries in Africa, with regard to the surface 
area. The low national income and meager resources resulted in poor health 
services to the needy communities. The civil war and the displacement of 
population has complicated the health problems and helped the spread of 
infectious diseases in the different parts of the country. Although TB is known 
to be endemic in Sudan, little information is available about the burden of the 
disease, its epidemiology, or extent of drug resistance problem (El-Sony et al 
2000). A recent global WHO/IUATLD project on anti-tuberculosis drug 
resistance surveillance showed a prevalence of drug resistance among new 
cases of higher than 10% in more than 30 countries and also identified 14 
countries where the incidence of multidrug-resistant tuberculosis (MDRTB) 
was more than 3% among new cases (Espinal et al 2001). 
The present study revealed high frequency of HIV (10%) among the study 
population, this was slightly higher than that reported by SNAP 1999 (7.2%). 
however, this result was in agreement with that obtained by the NTP in 2009 
and 2010 which reported 11.5% and 11.25% respectively in Khartoum state 
and all over Sudan was 12.1%. While another study by Awad-Elkareem 
(2010), revealed 14.6% which was higher than all previous studies. 4% was 
reported in year 2000 by El-Sony et al. The HIV prevalence among TB patients 
has a considerable influence on TB epidemiology. Because of the high risk of 
developing clinical TB in HIV infected persons, the recent increase in case 
load of HIV from 7.2 in 1999 to 10% in 2011 in the current study, will put the 
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additional strain on national TB control program. TB is the only HIV-
associated respiratory infection that is easily transmitted via the respiratory 
route among persons with HIV infection and from them, to non HIV infected 
persons. 
The prevalence of HIV in the Philippines was extremely low (0.006%) among 
blood donors, and overseas Filipino work visa applicants (0.001%) (Yanase, et 
al. 2007). These findings were totally in disagreement with present study; and 
this may be attributed to differences of study population who enrolled in 
previous study. Most of this showed very low prevalence, which may be 
attributed to the type of the patients who enrolled in previous study. Most of 
them were non TB patients while in present study all of them were TB patients. 
Fatkenheuer et al., (1999) mentioned that HIV is more present among people 
with TB than within the whole population. In the current study males were 
more prone to HIV infection compared with female and this finding was in 
agreement with Awad-Elkareem (2010).However, the study hypothesized that 
it could be attributed to different patterns of sexual activity or higher rates of 
injecting drug among males. All these studies regardless of types of screening 
of HIV emphasized and posed the greatest infectious hazard within the 
community and health care settings. 
In 2006, in Kwazulu-natal in South Africa the HIV prevalence among women 
in antenatal clinics was more than 39% (Cohen et al 2010), that reflected the 
high dissemination of HIV in that country which revealed disagreement with 
the present study finding. 
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The findings of the present study in regard to the tribes according to the area of 
origin showed that, TB was distributed in all parts of the country with varying 
rates, where the highest incidence of tuberculosis was reported in Khartoum 
state. Kordofanian tribes constitute about 25.4% of this rate, and this may be 
attributed to increased rates of migration of the Kordofanian people to 
Khartoum State due to the drought that occurred in Kordofan in the early 
eighties of the 20th century. In Southern States and Darfur States the rates of 
infection were 16.3% and 10.7% respectively, the migration from these States 
was due to the civil war that was running in these areas. In Kassala and red sea 
(4.8 %) the migration to Khartoum was very few, although they were 
considered as areas of high burden of TB/HIV, while Gadaref (0.4%) is stable 
and rich area. The tribes that showed the highest prevalence of TB infection 
were Denka (11.9%), Nuba (7.5%), Hamar (4.4%) and Jaalien (4%). 
Approximately similar findings were obtained by El-Eragi (2004). The 
possibility of genetic predisposition of members of these tribes should be 
considered, since many reports worldwide stated that, genetic factors were 
involved in the process of TB infection (Bellamy et al 1999, Bellamy  et al 
2000 and Abel and Casanova  2000). 
It is clearly TB patients in the current study have an age range between 15 to 
54 years (81%) and this finding agreed with study by Murray et al (1990) who 
revealed that most TB patients, 80% hah ages less than 50 years. This is the 
case in most developing countries, whereas in Europe TB was more prevalent 
in elder people due to other factors such as diabetes mellitus and also among 
immunocompormise patients. 
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This study illustrated that the males were more prone to infections than 
females, 70% of males and 30% of females. Also similar results had been 
obtained by Hassan (2010), Mohamed -Nour (2010); who showed that males 
were 68%, while females were 32%. This result might also had been due to 
social behaviour where females fear of social stigma beside the treatment 
seeking behaviour where females do not decide by themselves to seek medical 
assistance, or may be due to the increased consumption of cigarette and alcohol 
that had a significant role in increasing the risk for males. In the current study 
there was a significant correlation between infection and consumption of 
cigarette (30%) of males and also (12, 3%) of males drinking alcohol (P £ 
0.001). El Sony et al (2003) and Bellamy et al (2000) reported that an X 
chromosome susceptibility gene may contribute to a high frequency of males 
with tuberculosis observed in many populations. In a previous study in cows 
(Hassan  2010), the infected male were 90% and female were 10%, that 
reflected effect of sex in the disease which was observed and this may be due 
to the role of X chromosome contribution in the disease. In a study by El-Sony 
et al., 2002, they found no association between HIV status in TB patients and 
sex was found. 
There was no significant correlation between education or occupation and 
infection. In spite of this the current study showed that absence of growth 
slightly higher among non educated patients and this may be attributed to the 
quality of specimens. In addition no clear or significant association between 
education and drug resistance (P ³ 0.3) has shown, but it was very clear that 
most study population with different categories were found to be of low level 
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of education and consequently the dissemination of infection, was common due 
to the low income level and poor health services in their communities and this 
may increase the distribution of drug resistance. 
According to the marital status of the study population enrolled in the present 
study ,most of them were married (55.9%), simultaneously most of were males 
who were responsible for financial support and this situation may constitute a 
reduction of economic factor which is considered to be an important risk factor 
for dissemination of infection. 
The results DPCR and mPCR were completely concordant with those obtained 
by conventional culture testing. The identification of the species of 
mycobacteria is a very important issue, though non-tuberculosis species may 
be less pathogenic than M.TB, but they may cause clinically serious disease 
especially in immunocompromised patients. Six clinical isolates could not be 
identified to the, species level. They were identified as NTM by culture 
characteristics and multiplex-PCR, these isolates must receive more detailed 
study, l8 out 25 patients who were reactive for HIV, had typical mycobacteria 
complex, three have atypical mycobacteria, and four showed no growth, and 
this finding was totally agreement with study by Maghzob (2010) who reported 
84% of patients with HIV were found infected with MTB while 16% were co-
infected with NTM. 
Drug sensitivity tests using proportion method did for 241 clinical isolates 235 
out of them were typical mycobacterium complex, showed 46% were resistant 
to one or more of the drug tested, out of them 7.7% were MDR, 14% of clinical 
isolates were resistant to rifampcin and also 14% were to isoniazid, 33.6% 
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were resistant to streptomycin and 19.5% were resistant to ethambutol, while 
other six clinical isolates were atypical mycobacteria. These results were 
slightly higher than the results by Hassan 2010, which showed resistance to 
rifampcin (8%), isoniazid (13%), streptomycin (34%), and ethambutol (12%). 
Mono-resistance to each of the four first line anti-tuberculosis drugs was (0%) 
rifampcin, 1% isoniazid, l8% streptomycin and 3% ethambutol. The remaining 
61 isolates were sensitive to the drugs used in the test. In the current study 
Mono-resistant to the four first line anti- tuberculosis drugs was 1.7% 
rifampcin, 2.1% isoniazid, 17.4% streptomycin, 3% ethambutol and pan 
sensitive to rest of isolates were 54%.In the current study the six clinical 
isolates that were atypical mycobacteria, showed resistance to all of the above 
mentioned anti-tubercular drugs, and this may be attributed to the difference of 
mechanisms of drug susceptibility between M.TB and NTM an d this was 
confirmed by several studies that had illustrated the mechanisms of drug 
susceptibility of NTM are quite different and distinct from M. tuberculosis On 
the other hand mutations in gene targets like rpoB which have been found to be 
responsible for drug resistance to rifampcin in most isolates of M. tuberculosis. 
There are much lesser important in case of NTM (Meier  et al., 1994, Portillo 
Gomez et al 1995, Katoch 1997). 
The strategy followed in this study was detecting of isoniazid, rifampcin and 
ethambutol resistance in smear-positive specimens using MAS-PCR method in 
comparison with the conventional proportion method as a gold standard 
method that could detect the most prevalent targets of anti-tubercular drugs 
resistance. 
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The majority of isoniazid-resistant isolates (84%) were found to be associated 
with katG 315 gene. This agreed with another study which showed that (93%) 
isoniazid-resistant isolates carried this mutation (Dymova et al., 2011). Hence, 
this genetic mutation could be selected for detection of most isoniazid-resistant 
mycobacterial isolates. Regarding rifampcin, the majority were found to be 
associated with genes of rpoB 531 and rpoB526 (70% and 23.3% 
respectively). Several studies agreed with findings of the present study, such as 
Mokrousov et al (2003) who mentioned that mutations in the catalyst region of 
the rpoB gene are associated with the development of resistance to rifampcin. 
In 86% of occurrences, they arise at codons 531,526, or 516.Another study 
illustrated the mutation of rifampicin-resistant isolates were predominant at 
codons 531, 526, and 516 of the rpoB gene (73%, 12.55 % and 8% 
respectively) (Nikolayevskyy et al., 2007). 
In a previous study by Yang, et al. (2005), 174 clinical isolates of M. 
tuberculosis were obtained from Turkey, distinct PCR banding patterns were 
observed for different mutation profiles and the correlation between MAS-PCR 
results and DNA sequencing findings was 99.4%. With culture-based 
phenotypic drug susceptibility testing as a reference standard, the sensitivity 
and specificity of the newly developed MAS-PCR assay for drug resistance-
related genetic mutation detection were determined to be 8 1.1% and 97.5% for 
INH, 93.0% and 98.9 % for RIF, and 54.5% and 68.0 % for ethambutol. In the 
current study the sensitivity and specificity of MAS-PCR compared with 
phenotypic drug sensitivity tests using proportion method were 87.9% and 99.5 
% for rifampcin, 73% and 99.5% for isoniazid, 67.4% and 86.8% for 
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ethambutol, in comparing with the study by Hassan,(2010) approximately 
similar results obtained which gave the sensitivity and specificity of MAS-PCR 
compared with phenotypic drug sensitivity tests were 87.5% and 96.7% for 
rifampcin, 76.9% and 89.7% for isoniazid, 66.7% and 90.9% for ethambutol. 
Regarding EMB resistance several studies have shown that mutations might 
occur in other codons, such as mutations in Phe330Val and Thr630Ile of the 
emb gene (Ramaswamy et al., 2000). The relatively poor sensitivity and 
specificity of the MAS-PCR for EMB resistance detection indicates that 
additional better genetic markers for EMB resistance genetic markers need to 
be found and incorporated in the assay. 
The specificity of the MAS-PCR in comparison with the proportion method 
was found to be comparable except for that of EMB as reported by Yang et al. 
(2005), and Hassan (2010). 
In terms of sensitivity, the conventional proportion method was found to be 
obviously superior in detection of drug resistance, than the detecting capacity 
of MAS-PCR. This was in agreement with Yang et al., 2005 and Hassan 
(2010). To increase the sensitivity of MAS-PCR for detection MDR-TB more 
additional genes need to be included in reaction. 
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CONCLUSIONS 
The present study revealed the dissemination of pulmonary TB and HIV 
infections in different locations of Khartoum state. All age groups for both 
sexes and the different Sudanese tribes were affected with TB and HIV at 
varying rates.  
Through the work high rates of drug resistance were found. The study 
ascertained that drug resistant TB, and particularly multidrug-resistant TB 
(MDR-TB) is a serious problem for Sudan. 
High rates of initial drug resistance were detected among pulmonary isolates of 
M.TB during the current study in Sudan, 46% were resistant to one or more of 
the drugs tested, with 7.7% being multi-drug resistant. 
The molecular assay is emphasized as a highly accurate screening tool for 
MDR TB, which achieves a substantial reduction in diagnostic delay. 
MAS-PCR assay can therefore be suggested as a simple and rapid tool for 
detecting with high probability for the INH resistance in M. tuberculosis 
clinical strains. In terms of sensitivity, the conventional proportion method was 
found to be obviously superior in detection of drug resistance, than the 
detecting capacity of MAS-PCR. 
The antibiotic susceptibility of some of NTM species may be quite different to 
that of M. tuberculosis. 
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RECOMMENDATIONS 
· There is a growing need to identify mycobacterial isolates to species 
level to prevent the epidemic spreading of nosocomial and community 
infections from diagnosed and undiagnosed tuberculosis cases. 
·  It is highly important to integrate research and TB/HIV disease 
surveillance between programs and medical institutions, as it helps and 
simplifies the designing of control program against TB/HIV infection and 
to minimize the threat of tuberculosis and HIV. 
·  Early detection of tuberculosis resistance is crucial in initiating treatment 
and interrupting the transmission of primary drug resistance. 
·  To increase the sensitivity Of MAS-PCR for detection MDR-TB further 
studies are needed to add more genes or codons to be included in 
reaction. 
· The increasing incidence of MDRTB worldwide has placed emphasis on 
the need further research for early detection of drug resistance and 
therefore, also the need for earnest search for new drugs. 
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Appendix 
Appendix 1:-   Smear Preparation Procedures: 
1. Sputum Smear Preparation: 
1.  Label a new, clean, unscratched slide at one end with the relevant patient 
number. 
2.  Transfer an appropriate portion of the specimen to the slide by using an 
applicator stick or bacteriological loop. 
3.  Smear the specimen on the slide over an area approximately 2.0x1.0 cm. 
Make it thin enough to be able to read through. 
4.  Allow smear to air dry for 15 minutes. Do not use heat for drying. 
5.  Fix smears to the slides by pass slides through a flame three or four times 
with the smear uppermost. Do not over heat. Allow cooling before 
staining. 
6.  Discard the applicator stick in disinfectant and use a new one for each 
specimen 
Remove the particles of adherent sputum from the loops by moving it 
up and down through a flask containing sand and 70 % alcohol. Flame the 
bacteriological loop thoroughly prior to re-use. 
2. Ziehl-Neelsen Staining(WHO): 
Reagents: 
3% Fuchcin 
Basic Fuchcin…………………………………… 3.0g 
95% Ethanol………………………………………100ml      soln.1 
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Phenol 
Phenol crystals………………………………..……5.0g 
Distilled water…………………………………… 100ml…..soln.2 
                       (Gentle heat may be required) 
Working Solution: 
Combine 10ml of soln.1 with 90ml of soln.2 and store in an amber bottle at 
R.T. for 6-12 months and filter before use. 
Counter stain:  
Methylene Blue  
Methylene blue………………………………….1.0g 
Distilled water…………………………………..1000ml 
Store in an amber bottle at R.T. for 6-12 months. 
Decolorizing agent: 
25% sulphuric acid  
Conc. Sulphuric acid ………………………………25ml 
Distilled water…………………………………….100ml 
carefully add conc. Sulphuric acid to water, store at R.T. for 6-12 months. 
A. Ziehl-Neelsen Staining Procedure: 
1. Place the numbered slides on staining rack in batches  (maximum 12). 
Ensure that slides do not touch each other. 
2. Flood entire slides with Z.N Carbolfuchcin for 5-10 mins.  
3. Heat the slides slowly until its formation of steam appeared 
4. Rinse each slide individually in a gentle stream of running water until 
all free stain is washed away. 
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5. Flood the slide with the decoloursing solution for a maximum of 3 mins 
6. Rinse the slide thoroughly with water. Drain excess water from the 
slide. 
7. Flood the slide with counterstain. 
8. Allow the smear to counterstain for 60 seconds. 
9. Rinse the slide thoroughly with water. Drain excess water from the 
slide. 
10. Allow smear to air dry. 
Appendix 11:Preparation of Culture Media: 
Lowenstein - Jensen medium: 
1-          LJ medium is most widely used for tuberculosis culture. The 
modification of the International Union Against Tuberculosis and Lung 
Diseases (IUATLD) is recommended. 
2- LJ medium containing glycerol favors the growth of M. tuberculosis 
while LJ medium without glycerol but containing pyruvate encourage the 
growth of M. bovis.  
1-Ingredients 
2-Mineral salt solution 
Potassium dihydrogen phosphate anhydrous (KH2PO4)……..2.4 g 
Magnesium sulphate (MgSO4.7H2o)………………………...0.24 g    
Magnesium citrate…………………………………………… 0.6 g 
Asparagine……………………………………………………3.6 g               
Glycerol ……………………………………………………..12 ml                
 Distilled water ……………………………………………..600 ml    
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  Dissolve the ingredients in the distilled water by heating. Autoclave at 
121º C for 30 min. to sterilize. Cool to room temperature.    
Malachite Green solution, 2 %: 
Malachite green dye ………………………………………….2.0 g   
Sterile distilled water  ………………………………………100 ml 
Using a septic techniques dissolve the dye in sterile distilled water by 
placing the solution in the incubator for 1-2 hours. 
Homogenized whole eggs:   
 Fresh hen eggs, not more than 4-5 days old,  are cleaned by scrubbing 
thoroughly with a hard brush in warm water and plain alkaline soap. Let the 
eggs soak for 15-30 min. in the soap solution. Rinse eggs thoroughly in 
running water and soak them in 70 % ethanol for 15 min. Before handling 
the clean dry eggs scrub the hands and wash them. Crack the eggs with a 
sterile knife into a sterile blender. 
Preparation of complete medium 
The following ingredients are a aseptically pooled in a large, sterile flask 
and mixed well:        
Mineral salt solution ………………………………………..600 ml                    
Malachite green solution ……………………………………..20 ml              
Homogenized eggs (20-25) …………………………………..1000 ml 
The complete medium is distributed in 6-8 ml volumes in sterile 14 ml or 
28 ml McCartney or universal bottles or in 15-20 ml volumes in 20x150 
mm screw-capped test tubes, and the tops are securely fastened.   
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LJ media with pyruvate: 
The as previous but glycerol is omitted and 8.0 g Sodium pyruvate is added to 
the mineral solution. Thus LJ medium is enriched with 0.5 % Sodium pyruvate.   
Coagulation of medium: 
  Before loading, heat the inspissator to 80-85º C to quicken the build-up of the 
temperature. Place the bottles in a stand position in the inspissator and 
coagulate the medium for 45 minutes at 80-85º C.   
Sterility check: 
After inspissations, the whole media batch or a representative sample of culture 
bottles should be incubated at 35-37º C for 24 hours as a check of sterility. 
Storage 
The LJ medium should be dated and stored in the refrigerator and can be kept 
for several weeks if the caps are tightly closed to prevent drying out of the 
medium. 
 
 
 
 
 
 
 
 
 
Please purchase PDFcamp Printer on http://www.verypdf.com/ to remove this watermark.
 162
Appendix III:-Decontamination of Specimens 
A.  Conventional Petroff’s Method: 
Without centrifugation &with neutralization:  
1-Transfer the sputum into a 50 ml centrifuge tube. 
2-Add an equal volume of 1N Sodium hydroxide, close the bottle tightly, and 
mix thoroughly by shaking or vortex briefly. 
3-Keep at R.T. for 20 minutes. 
4-Add neutralizer 1N Hydrochloric acid with phenol red until the solution 
becomes yellow to clear ( usually about 5 or 6 ml fast, then drop by drop), with 
shaking. 
5-Inoculate 4 drops on slope of LJ media. 
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Appendix IV: Genscreen ULTRA HIV Ag-Ab 
 
LABEL NATURE OF THE REAGENTS 
R1 Microplate 
R2 
Concentrated washing solution (20x) 
R3 Negative control 
R4 HIV Ab positive control 
R5 HIV Ag positive control 
R6 Conjugate1 
R7a Conjugate2 
R7b Conjugate2 Diluent 
R8 Peroxidase substrate Buffer 
R9 Chromogen 
R10 Stopping solution 
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 ϦϜδϟ΍ϡϮσήΨϟ΍ΔϳϻϭϞΧ΍Ω  
ϡϮσήΨϟ΍ΔϳϻϭΝέΎΧ  
ΖѧγϦѧϣήѧΜϛϻϡϮѧσήΨϟ΍ϰѧϓϢϴѧϘϣ
έϮϬη 
  
 ϦϜδϟ΍ϥ΍ϮϨϋ   
 ϰϠѧλϷ΍ϦσϮѧϤϟ΍ήѧϬϧϭΔϴϟΎϤѧθϟ΍
ϞѧϴϨϟ΍ϡϮѧσήΨϟ΍ϞѧϴϨϟ΍ϭΓήѧϳΰΠϟ΍
έΎϨѧѧѧγϭξϴѧѧѧΑϷ΍ϕέίϷ΍ϞѧѧѧϴϨϟ΍
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ΔϴΑϮϨΠϟ΍ΕΎϳϻϮϟ΍  
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ΚѧϟΎΜϟ΍ϭ΃ϰϧΎѧΜϟ΍ήϬѧθϟ΍ϝΎѧϤϛ·ΪόΑϑΎϔΘϟ΍
ΔѧγΎϜΘϧ΍ΝϼѧϋϊѧτϗϞѧθϓ
Νϼόϟ΍ΓΩΎϋ·Ϟθϓ 
 ΍Ϋ΍ϦѧϣϞѧϗ΃ϊτϗήϬη 
 
ήϬηϦϣήΜϛ΃ϊτϗ  
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Ϣόϧϻ    
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Ϊμϟ΍ϰϓϯίέΔΤϛˬέΪѧμϟ΍ϰѧϓϢϟ΍
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